FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Tanimine, N
   Germana, SK
   Fan, M
   Hippen, K
   Blazar, BR
   Markmann, JF
   Turka, LA
   Priyadharshini, B
AF Tanimine, Naoki
   Germana, Sharon K.
   Fan, Martin
   Hippen, Keli
   Blazar, Bruce R.
   Markmann, James F.
   Turka, Laurence A.
   Priyadharshini, Bhavana
TI Differential effects of 2-deoxy-D-glucose on in vitro expanded human
   regulatory T cell subsets
SO PLOS ONE
LA English
DT Article
ID METABOLISM; ACTIVATION; INDUCTION; EXPANSION; RECEPTOR; SIGNALS
AB Regulatory T cells (Tregs) are required for the maintenance of immune tolerance and adoptive Treg infusion therapy has become a promising approach to suppress immune responses in diseases such as autoimmunity and transplant rejection. However, one critical challenge of Treg therapy is the requirement of in vitro expansion of functionally stable Tregs while preventing either the contamination of T effector and/or emergence of unstable pathogenic Tregs. Recent studies showing distinct metabolic requirements of T effectors and Tregs suggest that manipulation of cell metabolism may be an attractive strategy to achieve this goal. Here we show that human thymically derived Tregs (tTregs) and in vitro induced Tregs (iTregs) from naive T cells engage glycolysis equivalently upon activation. However, inhibiting glucose metabolism via 2-deoxy-D-glucose (2DG) has distinct effects on each of these subsets. While 2DG treatment at the onset of activation significantly reduced the proliferation and expression of suppressive molecules such as ICOS and CTLA-4 in tTregs, its effect on FOXP3 expression was small. In contrast, 2DG treatment during iTreg induction modestly decreased their proliferation but strongly reduced both ICOS and FOXP3 expression. Importantly, both Treg subsets became insensitive to 2DG after day 3 post activation with little effect on either proliferation or FOXP3 expression while T conventional Th0 cells showed reduced proliferation under the same conditions. Moreover, 2DG treatment at day 3 did not impair the suppressive capabilities of Treg subsets. Collectively, these findings suggest that there is a distinct temporal requirement of glycolysis in each of the activated human Treg subsets and T conventional cells. Furthermore, 2DG treatment at the onset as a strategy to impair contaminating T effector cell proliferation is unfavorable for optimal Treg generation as well.
C1 [Tanimine, Naoki; Germana, Sharon K.; Fan, Martin; Markmann, James F.; Turka, Laurence A.; Priyadharshini, Bhavana] Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02114 USA.
   [Hippen, Keli; Blazar, Bruce R.] Univ Minnesota, Canc Ctr, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplantat, Minneapolis, MN USA.
   [Turka, Laurence A.; Priyadharshini, Bhavana] Rheos Med, Boston, MA USA.
RP Priyadharshini, B (reprint author), Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02114 USA.; Priyadharshini, B (reprint author), Rheos Med, Boston, MA USA.
EM bpriyadharshini@rheosrx.com
FU NIH [P01HL018646]; Naito Foundation; Uehara Memorial Foundation
FX This work was supported by NIH grant P01HL018646 to LAT, Grant for
   Studying Overseas from The Naito Foundation to NT, and Research
   Fellowship from The Uehara Memorial Foundation to NT. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Angelin A., 2017, CELL METAB
   Bailey-Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016
   Blagih J, 2015, IMMUNITY, V42, P41, DOI 10.1016/j.immuni.2014.12.030
   BLUESTONE JA, 2015, SCI TRANSL MED, V7
   Chang CH, 2016, NAT IMMUNOL, V17, P364, DOI 10.1038/ni.3415
   Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016
   Cretenet G, 2016, SCI REP-UK, V6, DOI 10.1038/srep24129
   De Rosa V, 2015, NAT IMMUNOL, V16, P1174, DOI 10.1038/ni.3269
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Gerriets V. A., 2016, NAT IMMUNOL
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Howie D, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89160
   Huynh A, 2015, NAT IMMUNOL, V16, P188, DOI 10.1038/ni.3077
   Jones N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01516
   Kawalekar OU, 2016, IMMUNITY, V44, P380, DOI 10.1016/j.immuni.2016.01.021
   Kishore M, 2017, IMMUNITY, V47, P875, DOI 10.1016/j.immuni.2017.10.017
   MATHEW JM, 2018, SCI REP, V8
   Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613
   Priyadharshini B., 2018, J IMMUNOL
   Procaccini C, 2016, IMMUNITY, V44, P406, DOI 10.1016/j.immuni.2016.01.028
   Putnam AL, 2009, DIABETES, V58, P652, DOI 10.2337/db08-1168
   Renner K, 2015, EUR J IMMUNOL, V45, P2504, DOI 10.1002/eji.201545473
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x
   Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278
   Tang QZ, 2017, J CLIN INVEST, V127, P2505, DOI 10.1172/JCI90598
   Tanimine N., 2017, TRANSPLANTATION
   Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028
   Wang J, 2009, J IMMUNOL, V183, P4119, DOI 10.4049/jimmunol.0901065
   Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365
   Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873
   Xia LY, 2019, CELL METAB, V29, P103, DOI 10.1016/j.cmet.2018.09.020
   Yadav M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00232
   Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297
NR 34
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2019
VL 14
IS 6
AR e0217761
DI 10.1371/journal.pone.0217761
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IB4TA
UT WOS:000470263700054
PM 31170216
OA DOAJ Gold
DA 2019-07-08
ER

PT J
AU Candia, E
   Reyes, P
   Covian, C
   Rodriguez, F
   Wainstein, N
   Morales, J
   Mosso, C
   Rosemblatt, M
   Fierro, JA
AF Candia, Enzo
   Reyes, Paz
   Covian, Camila
   Rodriguez, Francisco
   Wainstein, Nicolas
   Morales, Jorge
   Mosso, Claudio
   Rosemblatt, Mario
   Alberto Fierro, Juan
TI Single and combined effect of retinoic acid and rapamycin modulate the
   generation, activity and homing potential of induced human regulatory T
   cells
SO PLOS ONE
LA English
DT Article
ID FOXP3 EXPRESSION; TGF-BETA; MAMMALIAN TARGET; IL-2 RECEPTOR; VITAMIN-A;
   IN-VITRO; EX-VIVO; EXPANSION; INDUCTION; CD4(+)
AB Adoptive transfer of CD4+CD25+FOXP3+regulatory T cells (Treg cells) has been successfully utilized to treat graft versus host disease and represents a promising strategy for the treatment of autoimmune diseases and transplant rejection. The aim of this study was to evaluate the effects of all-trans retinoic acid (atRA) and rapamycin (RAPA) on the number, phenotype, homing markers expression, DNA methylation, and function of induced human Treg cells in short-term cultures. Naive T cells were polyclonally stimulated and cultured for five days in the presence of different combinations of IL-2, TGF-beta 1, atRA and RAPA. The resulting cells were characterized by the expression of FOXP3, activation, surface and homing markers. Methylation of the Conserved Non-coding Sequence 2 was also evaluated. Functional comparison of the different culture conditions was performed by suppression assays in vitro. Culturing naive human T cells with IL-2/TGF beta 1 resulted in the generation of 54.2% of Treg cells (CD4+CD25+FOXP3+) whereas the addition of 100 nM atRA increased the yield of Treg cells to 66% (p = 0.0088). The addition of RAPA did not increase the number of Treg cells in any of these settings. Treg cells generated in the presence of atRA had an increased expression of the beta 7 integrin to nearly 100% of the generated Treg cells, while RAPA treated cells showed enhanced expression of CXCR4. The differential expression of homing molecules highlights the possibility of inducing Treg cells with differential organ-specific homing properties. Neither atRA nor RAPA had an effect on the highly methylated CNS2 sites, supporting reports that their contribution to the lineage stability of Treg cells is not mediated by methylation changes in this locus. Treg cells generated in the presence of RAPA show the most potent suppression effect on the proliferation of effector cells.
C1 [Candia, Enzo; Morales, Jorge; Mosso, Claudio; Alberto Fierro, Juan] Clin Las Condes, Ctr Trasplantes, Santiago, Chile.
   [Reyes, Paz; Rosemblatt, Mario] Fdn Ciencia & Vida, Santiago, Chile.
   [Covian, Camila; Rodriguez, Francisco; Wainstein, Nicolas; Rosemblatt, Mario] Univ Andres Bello, Fac Ciencias Biol, Santiago, Chile.
   [Rosemblatt, Mario] Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile.
RP Fierro, JA (reprint author), Clin Las Condes, Ctr Trasplantes, Santiago, Chile.
EM afierro@clc.cl
FU Fondecyt [1120731]; Conicyt Proyecto basal [PFB-16]; Direccion Academica
   Clinica Las Condes
FX This work was supported by Fondecyt 1120731, Conicyt Proyecto basal
   PFB-16, Direccion Academica Clinica Las Condes 2011, Julio Krauss
   Rotter. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Aoyama K, 2013, BLOOD, V122, P2125, DOI 10.1182/blood-2012-11-470252
   Apostolidis SA, 2016, NAT IMMUNOL, V17, P556, DOI 10.1038/ni.3390
   Baan CC, 2005, TRANSPLANTATION, V80, P110, DOI 10.1097/01.TP.0000164142.98167.4B
   Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932
   Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338
   Battaglia M, 2012, METHODS MOL BIOL, V821, P279, DOI 10.1007/978-1-61779-430-8_17
   Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719
   Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134
   Brown CC, 2015, EUR J IMMUNOL, V45, P1287, DOI 10.1002/eji.201344398
   Brunstein CG, 2016, BLOOD, V127, P1044, DOI 10.1182/blood-2015-06-653667
   Canavan JB, 2016, GUT, V65, P584, DOI 10.1136/gutjnl-2014-306919
   Cassani B, 2012, MOL ASPECTS MED, V33, P63, DOI 10.1016/j.mam.2011.11.001
   Chen LC, 2016, J IMMUNOL, V197, P1137, DOI 10.4049/jimmunol.1600696
   Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540
   Cimbro R, 2012, BLOOD, V120, P2610, DOI 10.1182/blood-2012-06-434779
   Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005
   Desreumaux P, 2012, GASTROENTEROLOGY, V143, P1207, DOI 10.1053/j.gastro.2012.07.116
   Di Ianni M, 2011, BLOOD, V117, P3921, DOI 10.1182/blood-2010-10-311894
   Ding YZ, 2012, TRENDS IMMUNOL, V33, P174, DOI 10.1016/j.it.2012.01.002
   Dons EM, 2012, HUM IMMUNOL, V73, P328, DOI 10.1016/j.humimm.2011.12.011
   Duhen T, 2012, BLOOD, V119, P4430, DOI 10.1182/blood-2011-11-392324
   Dunkin D, 2014, DIGEST DIS, V32, P61, DOI 10.1159/000367827
   Elias KM, 2008, BLOOD, V111, P1013, DOI 10.1182/blood-2007-06-096438
   Engelhardt BG, 2011, BONE MARROW TRANSPL, V46, P436, DOI 10.1038/bmt.2010.127
   Ermann J, 2005, BLOOD, V105, P2220, DOI 10.1182/blood-2004-05-2044
   Evans-Marin HL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134100
   Fantus D, 2015, AM J TRANSPLANT, V15, P891, DOI 10.1111/ajt.13151
   Fantus D, 2015, TRANSPLANTATION, V99, pE117, DOI 10.1097/TP.0000000000000803
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Gallon L, 2015, TRANSPLANTATION, V99, P1774, DOI 10.1097/TP.0000000000000717
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   Geem D, 2015, INFLAMM BOWEL DIS, V21, P1409, DOI 10.1097/MIB.0000000000000343
   Geissler EK, 2013, CURR OPIN ORGAN TRAN, V18, P408, DOI 10.1097/MOT.0b013e328363319d
   Geissler Edward K, 2012, Transplant Res, V1, P11, DOI 10.1186/2047-1440-1-11
   Gerriets VA, 2016, NAT IMMUNOL, V17, P1459, DOI 10.1038/ni.3577
   Golovina TN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015868
   Guo YX, 2015, PHYSIOL REV, V95, P125, DOI 10.1152/physrev.00032.2013
   Habtezion A, 2016, GASTROENTEROLOGY, V150, P340, DOI 10.1053/j.gastro.2015.10.046
   Heazlewood SY, 2014, ANN NY ACAD SCI, V1310, P119, DOI 10.1111/nyas.12329
   Hill JA, 2008, IMMUNITY, V29, P758, DOI 10.1016/j.immuni.2008.09.018
   Himmel ME, 2012, IMMUNOLOGY, V136, P115, DOI 10.1111/j.1365-2567.2012.03572.x
   Hippen KL, 2011, AM J TRANSPLANT, V11, P1148, DOI 10.1111/j.1600-6143.2011.03558.x
   Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Hori S, 2012, NAT IMMUNOL, V13, P943, DOI 10.1038/ni.2424
   Hornero RA, 2017, TRANSPLANTATION, V101, P302, DOI 10.1097/TP.0000000000001278
   Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474
   Huter EN, 2008, EUR J IMMUNOL, V38, P1814, DOI 10.1002/eji.200838346
   Issa F, 2013, TRENDS IMMUNOL, V34, P107, DOI 10.1016/j.it.2012.11.003
   Issa F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053331
   Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011
   James CR, 2016, IMMUNOL CELL BIOL
   Jhunjhunwala S, 2013, J LEUKOCYTE BIOL, V94, P981, DOI 10.1189/jlb.0312167
   Jhunjhunwala S, 2012, J CONTROL RELEASE, V159, P78, DOI 10.1016/j.jconrel.2012.01.013
   Kang SG, 2007, J IMMUNOL, V179, P3724, DOI 10.4049/jimmunol.179.6.3724
   Kawamoto K, 2010, TRANSPL IMMUNOL, V23, P28, DOI 10.1016/j.trim.2010.03.004
   Kim CH, 2008, CLIN DEV IMMUNOL, P1, DOI 10.1155/2008/416910
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   Kim KW, 2015, IMMUNOLOGY, V144, P68, DOI 10.1111/imm.12351
   Kitagawa Y, 2017, NAT IMMUNOL, V18, P173, DOI 10.1038/ni.3646
   Koenecke C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038252
   Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584
   Lal G, 2009, J IMMUNOL, V182, P259, DOI 10.4049/jimmunol.182.1.259
   Lee JH, 2007, J IMMUNOL, V178, P301, DOI 10.4049/jimmunol.178.1.301
   Levitsky J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156535
   Lewis M, 2008, IMMUNOL CELL BIOL, V86, P226, DOI 10.1038/sj.icb.7100132
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Long SA, 2008, J AUTOIMMUN, V30, P293, DOI 10.1016/j.jaut.2007.12.012
   Lu L, 2014, P NATL ACAD SCI USA, V111, pE3432, DOI 10.1073/pnas.1408780111
   Lu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024590
   Lu L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015150
   Lu L, 2010, J IMMUNOL, V184, P4295, DOI 10.4049/jimmunol.0903418
   Lu Y, 2014, J IMMUNOL RES, V2014
   Ma JL, 2014, J LEUKOCYTE BIOL, V95, P275, DOI 10.1189/jlb.0513297
   Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478
   McMurchy AN, 2012, EUR J IMMUNOL, V42, P27, DOI 10.1002/eji.201141651
   Michael M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/608951
   Miyara M, 2016, ONCOTARGET
   Miyara M, 2014, NAT REV RHEUMATOL, V10, P543, DOI 10.1038/nrrheum.2014.105
   Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019
   Moore C, 2015, EUR J IMMUNOL, V45, P452, DOI 10.1002/eji.201444743
   Moreira-Teixeira L, 2012, J IMMUNOL, V188, P624, DOI 10.4049/jimmunol.1102281
   Morikawa H, 2014, IMMUNOL REV, V259, P192, DOI 10.1111/imr.12174
   Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697
   Nair VS, 2016, J IMMUNOL, V196, P2119, DOI 10.4049/jimmunol.1502352
   Nolting J, 2009, J EXP MED, V206, P2131, DOI 10.1084/jem.20090639
   Ohoka Y, 2011, J IMMUNOL, V186, P733, DOI 10.4049/jimmunol.1000913
   Okada M, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0129-1
   Pilat N, 2012, CURR OPIN ORGAN TRAN, V17, P63, DOI 10.1097/MOT.0b013e32834ee68b
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Putnam AL, 2009, DIABETES, V58, P652, DOI 10.2337/db08-1168
   Qian XF, 2011, INT IMMUNOPHARMACOL, V11, P630, DOI 10.1016/j.intimp.2010.11.036
   Bono MR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060349
   Ruiz P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00596
   Safinia N, 2016, ONCOTARGET, V7, P7563, DOI 10.18632/oncotarget.6927
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Sakaguchi S, 2011, METHODS MOL BIOL, V707, P3, DOI 10.1007/978-1-61737-979-6_1
   Sato K, 2002, J IMMUNOL, V168, P6263, DOI 10.4049/jimmunol.168.12.6263
   Schambach F, 2007, EUR J IMMUNOL, V37, P2396, DOI 10.1002/eji.200737621
   Schmidt A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148474
   Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200
   Scotta C, 2013, HAEMATOLOGICA, V98, P1291, DOI 10.3324/haematol.2012.074088
   Shi XD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093995
   Siewert C, 2007, EUR J IMMUNOL, V37, P978, DOI 10.1002/eji.200636575
   Simonetta F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113314
   Singh K, 2012, AM J TRANSPLANT, V12, P1441, DOI 10.1111/j.1600-6143.2011.03963.x
   Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473
   Tollervey JR, 2012, EPIGENETICS-US, V7, P823, DOI 10.4161/epi.21141
   Tomura M, 2010, J CLIN INVEST, V120, P883, DOI 10.1172/JCI40926
   Tran Dat Q, 2013, Methods Mol Biol, V979, P199, DOI 10.1007/978-1-62703-290-2_16
   Trzonkowski P, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7721
   Trzonkowski P, 2009, CLIN IMMUNOL, V133, P22, DOI 10.1016/j.clim.2009.06.001
   Turnquist HR, 2007, J IMMUNOL, V178, P7018, DOI 10.4049/jimmunol.178.11.7018
   Valmori D, 2006, J IMMUNOL, V177, P944, DOI 10.4049/jimmunol.177.2.944
   Veerapathran A, 2011, BLOOD, V118, P5671, DOI 10.1182/blood-2011-02-337097
   Wang J, 2009, J IMMUNOL, V183, P4119, DOI 10.4049/jimmunol.0901065
   Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042
   Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277
   Xu LL, 2010, IMMUNITY, V33, P313, DOI 10.1016/j.immuni.2010.09.001
   Yue XJ, 2016, J EXP MED, V213, P377, DOI 10.1084/jem.20151438
   Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297
   Zhang N, 2009, IMMUNITY, V30, P458, DOI 10.1016/j.immuni.2008.12.022
   Zheng SG, 2002, J IMMUNOL, V169, P4183, DOI 10.4049/jimmunol.169.8.4183
   Zheng SG, 2008, J IMMUNOL, V180, P7112, DOI 10.4049/jimmunol.180.11.7112
   Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
   Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007
   Zundler S, 2015, CLIN EXP RHEUMATOL, V33, pS19
NR 131
TC 6
Z9 7
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 26
PY 2017
VL 12
IS 7
AR e0182009
DI 10.1371/journal.pone.0182009
PG 32
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FB8EN
UT WOS:000406371800074
PM 28746369
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Trojan, K
   Unterrainer, C
   Weimer, R
   Bulut, N
   Morath, C
   Aly, M
   Zhu, L
   Opelz, G
   Daniel, V
AF Trojan, Karina
   Unterrainer, Christian
   Weimer, Rolf
   Bulut, Nuray
   Morath, Christian
   Aly, Mostafa
   Zhu, Li
   Opelz, Gerhard
   Daniel, Volker
TI Helios expression and Foxp3 TSDR methylation of IFNy plus and IFNy- Treg
   from kidney transplant recipients with good long-term graft function
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; IN-VITRO; IMMUNOSUPPRESSIVE DRUGS;
   ORGAN-TRANSPLANTATION; INTERFERON-GAMMA; DNA METHYLATION; SURVIVAL; VIVO
AB Background
   There is circumstantial evidence that IFNy+ Treg might have clinical relevance in transplantation. IFNy+ Treg express IFNy receptors and are induced by IFNy. In the present study we investigated in kidney transplant recipients with good long-term stable graft function the absolute cell counts of IFNy+ Treg subsets and whether their expression of Foxp3 is stable or transient.
   Method
   Helios expression determined by eight-color-fluorescence flow cytometry and methylation status of the Foxp3 Treg specific demethylation region (TSDR) served as indicators for stability of Foxp3 expression. Methylation status was investigated in enriched IFNy+ and IFNy-Treg preparations originating from peripheral blood using high resolution melt analysis. A total of 136 transplant recipients and 52 healthy controls were studied.
   Results
   Proportions of IFNy+ Treg were similar in patients and healthy controls (0.05% and 0.04% of all CD4+ lymphocytes; p = n.s.). Patients also had similar absolute counts of IFNy producing Helios+ and Helios-Treg (p = n.s.). Most of the IFNy+ and IFNy-Treg in transplant recipients had a methylated Foxp3 TSDR, however, there was a sizeable proportion of IFNy+ and IFNy-Treg with demethylated Foxp3 TSDR. Male and female patients showed more frequently methylated IFNy+ and IFNy-Treg than male and female controls (all p<0.05).
   Conclusions
   Kidney transplant recipients with good long-term stable graft function have similar levels of IFNy+ Treg as healthy controls. IFNy+ and IFNy-Treg subsets in patients consist of cells with stable and cells with transient Foxp3 expression; however, patients showed more frequently methylated IFNy+ and IFNy- Treg than controls. The data show increased levels of Treg subsets with stable as well as transient Foxp3 expression in patients with stable allograft acceptance compared to healthy controls.
C1 [Trojan, Karina; Unterrainer, Christian; Aly, Mostafa; Zhu, Li; Opelz, Gerhard; Daniel, Volker] Univ Heidelberg Hosp, Transplantat Immunol Inst Immunol, Heidelberg, Germany.
   [Weimer, Rolf; Bulut, Nuray] Univ Giessen, Dept Internal Med, Giessen, Germany.
   [Morath, Christian] Heidelberg Univ, Dept Nephrol, Heidelberg, Germany.
   [Aly, Mostafa] Assiut Univ, Dept Internal Med, Nephrol Unit, Assiut, Egypt.
   [Zhu, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Wuhan, Peoples R China.
RP Daniel, V (reprint author), Univ Heidelberg Hosp, Transplantat Immunol Inst Immunol, Heidelberg, Germany.
EM Volker.Daniel@med.uni-heidelberg.de
OI Daniel, Volker/0000-0001-8345-1031
CR Akimova T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024226
   Daniel V, 2008, TRANSPL INT, V21, P646, DOI 10.1111/j.1432-2277.2008.00662.x
   Daniel V, 2016, HUM IMMUNOL, V77, P146, DOI 10.1016/j.humimm.2015.11.006
   Daniel V, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0111-2
   Daniel V, 2014, INT REV IMMUNOL, V33, P195, DOI 10.3109/08830185.2013.845181
   Daniel V, 2013, HUM IMMUNOL, V74, P151, DOI 10.1016/j.humimm.2012.09.010
   Daniel V, 2012, TRANSPL IMMUNOL, V27, P114, DOI 10.1016/j.trim.2012.08.003
   Daniel V, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-47
   Daniel V, 2011, HUM IMMUNOL, V72, P699, DOI 10.1016/j.humimm.2011.05.020
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Getnet D, 2010, MOL IMMUNOL, V47, P1595, DOI 10.1016/j.molimm.2010.02.001
   Gottschalk RA, 2012, J IMMUNOL, V188, P976, DOI 10.4049/jimmunol.1102964
   Greenland JR, 2016, TRANSPLANTATION
   Grzanka J, 2013, INT IMMUNOPHARMACOL, V16, P343, DOI 10.1016/j.intimp.2013.02.004
   Hall BM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00208
   Himmel ME, 2013, J IMMUNOL, V190, P2001, DOI 10.4049/jimmunol.1201379
   Kim J, 2012, AM J RESP CRIT CARE, V185, P330, DOI 10.1164/rccm.201106-1026OC
   Marcen R, 2009, DRUGS, V69, P2227, DOI 10.2165/11319260-000000000-00000
   Mellor AL, 2011, J IMMUNOL, V186, P4535, DOI 10.4049/jimmunol.1002937
   Nakagawa H, 2016, P NATL ACAD SCI USA, V113, P6248, DOI 10.1073/pnas.1604765113
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Schmitt EG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00152
   Sebastian M, 2016, J IMMUNOL, V196, P144, DOI 10.4049/jimmunol.1501704
   Sela U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146412
   Tahvildari M, 2016, TRANSPLANTATION, V100, P525, DOI 10.1097/TP.0000000000001044
   Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028
   van der Net JB, 2016, TRANSPL INT, V29, P3, DOI 10.1111/tri.12608
   Wang LQ, 2013, MOL CELL BIOL, V33, P4106, DOI 10.1128/MCB.00144-13
   Zabransky DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034547
NR 29
TC 3
Z9 3
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 15
PY 2017
VL 12
IS 3
AR e0173773
DI 10.1371/journal.pone.0173773
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN9HQ
UT WOS:000396311700060
PM 28296931
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU He, XH
   Landman, S
   Bauland, SCG
   van den Dolder, J
   Koenen, HJPM
   Joosten, I
AF He, Xuehui
   Landman, Sija
   Bauland, Stijn C. G.
   van den Dolder, Juliette
   Koenen, Hans J. P. M.
   Joosten, Irma
TI A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity
   Treg Cells
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; IN-VIVO; CUTTING EDGE; RAPAMYCIN; EXPRESSION;
   INDUCTION; STABILITY; PHENOTYPE; PRESERVES; MECHANISM
AB Regulatory T cells (Treg) are important for immune homeostasis and are considered of great interest for immunotherapy. The paucity of Treg numbers requires the need for ex vivo expansion. Although therapeutic Treg flow-sorting is feasible, most centers aiming at Treg-based therapy focus on magnetic bead isolation of CD4+CD25+ Treg using a good manufacturing practice compliant closed system that achieves lower levels of cell purity. Polyclonal Treg expansion protocols commonly use anti-CD3 plus anti-CD28 monoclonal antibody (mAb) stimulation in the presence of rhIL-2, with or without rapamycin. However, the resultant Treg population is often heterogeneous and pro-inflammatory cytokines like IFN gamma and IL-17A can be produced. Hence, it is crucial to search for expansion protocols that not only maximize ex vivo Treg proliferative rates, but also maintain Treg stability and preserve their suppressive function. Here, we show that ex vivo expansion of low purity magnetic bead isolated Treg in the presence of a TNFR2 agonist mAb (TNFR2-agonist) together with rapamycin, results in a homogenous stable suppressive Treg population that expresses FOXP3 and Helios, shows low expression of CD127 and hypo-methylation of the FOXP3 gene. These cells reveal a low IL-17A and IFN gamma producing potential and hardly express the chemokine receptors CCR6, CCR7 and CXCR3. Restimulation of cells in a pro-inflammatory environment did not break the stability of this Treg population. In a preclinical humanized mouse model, the TNFR2-agonist plus rapamycin expanded Treg suppressed inflammation in vivo. Importantly, this Treg expansion protocol enables the use of less pure, but more easily obtainable cell fractions, as similar outcomes were observed using either FACS-sorted or MACS-isolated Treg. Therefore, this protocol is of great interest for the ex vivo expansion of Treg for clinical immunotherapy.
C1 [He, Xuehui; Landman, Sija; Koenen, Hans J. P. M.; Joosten, Irma] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Lab Med Immunol, NL-6525 ED Nijmegen, Netherlands.
   [Bauland, Stijn C. G.] Sanavisie Bodyclin, Mill, Netherlands.
   [van den Dolder, Juliette] Hycult Biotech, Uden, Netherlands.
RP Joosten, I (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Lab Med Immunol, NL-6525 ED Nijmegen, Netherlands.
EM Irma.Joosten@radboudumc.nl
RI Koenen, Hans/A-2852-2014
OI He, Xuehui/0000-0002-3801-4091
FU Sanavisie Bodyclinic; Hycult Biotech;  [NSFC61263039];  [NSFC11101321]
FX The funders (Sanavisie Bodyclinic and Hycult Biotech) provided support
   in the form of offering research materials e.g. human skins or
   TNFR2-agonist for authors (XH, SL, HJPM, and IJ), but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. The scientific
   roles of these authors are articulated in the "Author Contributions"
   section. XH is also supported by NSFC61263039 and NSFC11101321.
CR Annunziato F, 2002, J EXP MED, V196, P379, DOI 10.1084/jem.20020110
   Ashley CW, 2009, J IMMUNOL, V183, P4843, DOI 10.4049/jimmunol.0900845
   Baecher-Allan C, 2006, J IMMUNOL, V176, P4622, DOI 10.4049/jimmunol.176.8.4622
   Basu S, 2008, J IMMUNOL, V180, P5794, DOI 10.4049/jimmunol.180.9.5794
   Battaglia M, 2012, METHODS MOL BIOL, V821, P279, DOI 10.1007/978-1-61779-430-8_17
   Chen X, 2013, J IMMUNOL, V190, P1076, DOI 10.4049/jimmunol.1202659
   Chen X, 2010, EUR J IMMUNOL, V40, P1099, DOI 10.1002/eji.200940022
   Coenen JJA, 2006, BLOOD, V107, P1018, DOI 10.1182/blood-2005-07-3032
   de Oliveira VL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045509
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2
   He XH, 2014, J INVEST DERMATOL, V134, P975, DOI 10.1038/jid.2013.459
   Himmel ME, 2013, J IMMUNOL, V190, P2001, DOI 10.4049/jimmunol.1201379
   Hoffmann P, 2004, BLOOD, V104, P895, DOI 10.1182/blood-2004-01-0086
   Kim EY, 2006, J IMMUNOL, V176, P1026, DOI 10.4049/jimmunol.176.2.1026
   Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967
   Koenen HJPM, 2005, J IMMUNOL, V174, P7573, DOI 10.4049/jimmunol.174.12.7573
   Kreijveld E, 2007, BLOOD, V109, P244, DOI 10.1182/blood-2006-05-021931
   Lin CH, 2003, EUR J IMMUNOL, V33, P626, DOI 10.1002/eji.200323570
   Miller PG, 2015, J IMMUNOL, V195, P2633, DOI 10.4049/jimmunol.1500286
   Mougiakakos D, 2011, BLOOD, V117, P857, DOI 10.1182/blood-2010-09-307041
   Nadig SN, 2010, NAT MED, V16, P809, DOI 10.1038/nm.2154
   Nagar M, 2010, J IMMUNOL, V184, P3570, DOI 10.4049/jimmunol.0902070
   Nie H, 2013, NAT MED, V19, P322, DOI 10.1038/nm.3085
   Okubo Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03153
   Pahwa R, 2010, J IMMUNOL METHODS, V363, P67, DOI 10.1016/j.jim.2010.10.006
   Peters JH, 2013, BLOOD, V122, P2213, DOI 10.1182/blood-2013-03-489443
   Peters JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003161
   Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464
   Scotta C, 2013, HAEMATOLOGICA, V98, P1291, DOI 10.3324/haematol.2012.074088
   Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982
   Singer BD, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00046
   Singh K, 2012, AM J TRANSPLANT, V12, P1441, DOI 10.1111/j.1600-6143.2011.03963.x
   Tresoldi E, 2011, HAEMATOL-HEMATOL J, V96, P1357, DOI 10.3324/haematol.2011.041483
   van Mierlo GJD, 2008, J IMMUNOL, V180, P2747, DOI 10.4049/jimmunol.180.5.2747
   Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106
   Zeiser R, 2008, BLOOD, V111, P453, DOI 10.1182/blood-2007-06-094482
   Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747
NR 38
TC 19
Z9 19
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 25
PY 2016
VL 11
IS 5
AR e0156311
DI 10.1371/journal.pone.0156311
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DN2GI
UT WOS:000376881700084
PM 27224512
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Goldstein, JD
   Burlion, A
   Zaragoza, B
   Sendeyo, K
   Polansky, JK
   Huehn, J
   Piaggio, E
   Salomon, BL
   Marodon, G
AF Goldstein, Jeremie D.
   Burlion, Aude
   Zaragoza, Bruno
   Sendeyo, Kelhia
   Polansky, Julia K.
   Huehn, Jochen
   Piaggio, Eliane
   Salomon, Benoit L.
   Marodon, Gilles
TI Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells
   Reveals a Very Dynamic Regulation of Foxp3 Expression
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXP3; GENE-EXPRESSION; IN-VIVO;
   LYMPHOPROLIFERATIVE DISORDER; CIS-ELEMENT; TREG; INTERLEUKIN-2; SCURFY;
   LOCUS; MOUSE
AB The IL-2/JAK3/STAT-5 signaling pathway is involved on the initiation and maintenance of the transcription factor Foxp3 in regulatory T cells (Treg) and has been associated with demethylation of the intronic Conserved Non Coding Sequence-2 (CNS2). However, the role of the JAK/STAT pathway in controlling Foxp3 in the short term has been poorly investigated. Using two different JAK/STAT pharmacological inhibitors, we observed a detectable loss of Foxp3 after 10 min. of treatment that affected 70% of the cells after one hour. Using cycloheximide, a general inhibitor of mRNA translation, we determined that Foxp3, but not CD25, has a high turnover in IL-2 stimulated Treg. This reduction was correlated with a rapid reduction of Foxp3 mRNA. This loss of Foxp3 was associated with a loss in STAT-5 binding to the CNS2, which however remains demethylated. Consequently, Foxp3 expression returns to normal level upon restoration of basal JAK/STAT signaling in vivo. Reduced expression of several genes defining Treg identity was also observed upon treatment. Thus, our results demonstrate that Foxp3 has a rapid turn over in Treg partly controlled at the transcriptional level by the JAK/STAT pathway.
C1 [Goldstein, Jeremie D.; Burlion, Aude; Zaragoza, Bruno; Sendeyo, Kelhia; Salomon, Benoit L.; Marodon, Gilles] Univ Paris 06, Sorbonne Univ, UMR S CR7, CIMI,INSERM,U1135,CNRS,ERL 8255, Paris, France.
   [Polansky, Julia K.; Huehn, Jochen] Helmholtz Ctr Infect Res, Dept Expt Immunol, Braunschweig, Germany.
   [Piaggio, Eliane] Inst Curie, INSERM, U932, Paris, France.
   [Goldstein, Jeremie D.] Inst Biomed, Bellinzona, Switzerland.
   [Polansky, Julia K.] German Rheumatism Res Ctr, Expt Rheumatol, Charitepl 1, Berlin, Germany.
RP Marodon, G (reprint author), Univ Paris 06, Sorbonne Univ, UMR S CR7, CIMI,INSERM,U1135,CNRS,ERL 8255, Paris, France.
EM gilles.marodon@upmc.fr
RI marodon, gilles/E-7202-2017; Salomon, Benoit/M-2421-2017;
   Polansky-Biskup, Julia/J-5937-2017; gastinel, bibliotheque/K-6862-2017;
   Piaggio, Eliane/E-5260-2016
OI marodon, gilles/0000-0003-4889-6785; Salomon,
   Benoit/0000-0001-9673-5578; Polansky-Biskup, Julia/0000-0003-4727-2540;
   Piaggio, Eliane/0000-0002-2455-8442
FU ANR (Agence Nationale de la Recherche); AFM (Association Francaise
   contre les Myopathies); ANRS (Agence Nationale pour la Recherche contre
   le SIDA); German Research Foundation [CRC738, CRC854]
FX This study was funded by grants from the ANR (Agence Nationale de la
   Recherche), the AFM (Association Francaise contre les Myopathies) and
   the ANRS (Agence Nationale pour la Recherche contre le SIDA). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.r The authors wish
   to thank Dr Sylvie Gregoire, Mr Claude Baillou and Mr Bruno Gouritin
   (UMR 7211, CIMI) for cell sorting, Beatrice Levacher (INSERM U959) for
   quantitative qPCR, Dr Nicolas Cagnard (INSERM U580 and Bioinformatics
   Platform, Faculty of Medicine Paris Descartes, Paris) for transcriptome
   analysis, Dr Thierry Rose (Pasteur Institute) for sharing reagents, Dr
   Antonio Bandeira (Institut Pasteur) for the Scurfy samples, and Dr
   Nicolas Petit, Dr Audrey Baeyens, Dr Gaelle Martin, Dr Yenkel
   Grinberg-Bleyer for their help in various aspects of the work. DNA
   methylation experiments were developed and performed by Udo Baron and
   Sven Olek at Epiontis GmbH. This study was funded by grants from the ANR
   (Agence Nationale de la Recherche to BLS and GM), the AFM (Association
   Francaise contre les Myopathies to GM), the ANRS (Agence Nationale pour
   la Recherche contre le SIDA to GM) and by the German Research Foundation
   (CRC738 and CRC854 to JH).
CR Bailey-Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Bending D, 2014, J IMMUNOL, V193, P2699, DOI 10.4049/jimmunol.1400599
   Brown GR, 2000, BIOORG MED CHEM LETT, V10, P575, DOI 10.1016/S0960-894X(00)00051-2
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280
   Chen Q, 2011, J IMMUNOL, V186, P6329, DOI 10.4049/jimmunol.1100061
   Chen ZJ, 2013, IMMUNITY, V39, P272, DOI 10.1016/j.immuni.2013.08.006
   D'Cruz LM, 2005, NAT IMMUNOL, V6, P1152, DOI 10.1038/ni1264
   Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512
   Duarte JH, 2009, EUR J IMMUNOL, V39, P948, DOI 10.1002/eji.200839196
   Feng YQ, 2014, CELL, V158, P749, DOI 10.1016/j.cell.2014.07.031
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263
   Goldstein JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019038
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428
   Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852
   Lee SM, 2008, BLOOD, V111, P3599, DOI 10.1182/blood-2007-09-115014
   Li XD, 2014, CELL, V158, P734, DOI 10.1016/j.cell.2014.07.030
   Lio CWJQ, 2008, IMMUNITY, V28, P100, DOI 10.1016/j.immuni.2007.11.021
   Liu B, 2010, SCIENCE, V330, P521, DOI 10.1126/science.1193787
   Liu ZD, 2015, NATURE, V528, P225, DOI 10.1038/nature16169
   Luo XR, 2008, J IMMUNOL, V180, P2757, DOI 10.4049/jimmunol.180.5.2757
   Mouly E, 2010, J EXP MED, V207, P2113, DOI 10.1084/jem.20092153
   Murawski MR, 2006, ANN NY ACAD SCI, V1079, P198, DOI 10.1196/annals.1375.031
   Ochs HD, 2001, NAT GENET, V27, P20, DOI DOI 10.1038/83713
   Ogawa C, 2014, J IMMUNOL, V192, P475, DOI 10.4049/jimmunol.1301892
   Ohkura N, 2013, IMMUNITY, V38, P414, DOI 10.1016/j.immuni.2013.03.002
   Oldenhove G, 2009, IMMUNITY, V31, P772, DOI 10.1016/j.immuni.2009.10.001
   Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077
   Passerini L, 2008, INT IMMUNOL, V20, P421, DOI 10.1093/intimm/dxn002
   Pesu M, 2008, NATURE, V455, P246, DOI 10.1038/nature07210
   Rouas R, 2009, EUR J IMMUNOL, V39, P1608, DOI 10.1002/eji.200838509
   Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996
   Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Soper DM, 2007, EUR J IMMUNOL, V37, P1817, DOI 10.1002/eji.200737101
   Stittrich AB, 2010, NAT IMMUNOL, V11, P1057, DOI 10.1038/ni.1945
   Tang Q, 2008, IMMUNITY, V28, P687, DOI 10.1016/j.immuni.2008.03.016
   van Loosdregt J, 2013, IMMUNITY, V39, P259, DOI 10.1016/j.immuni.2013.05.018
   van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118
   Wang Y, 2008, J IMMUNOL, V180, P1565, DOI 10.4049/jimmunol.180.3.1565
   Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707
   Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
   Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747
NR 46
TC 7
Z9 9
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2016
VL 11
IS 4
AR e0153682
DI 10.1371/journal.pone.0153682
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ3UH
UT WOS:000374131700103
PM 27077371
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Schmidt, A
   Eriksson, M
   Shang, MM
   Weyd, H
   Tegner, J
AF Schmidt, Angelika
   Eriksson, Matilda
   Shang, Ming-Mei
   Weyd, Heiko
   Tegner, Jesper
TI Comparative Analysis of Protocols to Induce Human CD4+Foxp3+Regulatory T
   Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and
   Butyrate
SO PLOS ONE
LA English
DT Article
ID VERSUS-HOST-DISEASE; DE-NOVO GENERATION; GROWTH-FACTOR-BETA; FOXP3
   EXPRESSION; RECEPTOR STIMULATION; SUPPRESSIVE FUNCTION; PROMOTES
   GENERATION; EPIGENETIC CHANGES; IN-VIVO; DIFFERENTIATION
AB Regulatory T cells (Tregs) suppress other immune cells and are critical mediators of peripheral tolerance. Therapeutic manipulation of Tregs is subject to numerous clinical investigations including trials for adoptive Treg transfer. Since the number of naturally occurring Tregs (nTregs) is minute, it is highly desirable to develop a complementary approach of inducing Tregs (iTregs) from naive T cells. Mouse studies exemplify the importance of peripherally induced Tregs as well as the applicability of iTreg transfer in different disease models. Yet, procedures to generate iTregs are currently controversial, particularly for human cells. Here we therefore comprehensively compare different established and define novel protocols of human iTreg generation using TGF-beta in combination with other compounds. We found that human iTregs expressed several Treg signature molecules, such as Foxp3, CTLA-4 and EOS, while exhibiting low expression of the cytokines Interferon-gamma, IL-10 and IL-17. Importantly, we identified a novel combination of TGF-beta, retinoic acid and rapamycin as a robust protocol to induce human iTregs with superior suppressive activity in vitro compared to currently established induction protocols. However, iTregs generated by these protocols did not stably retain Foxp3 expression and did not suppress in vivo in a humanized graft-versus-host-disease mouse model, highlighting the need for further research to attain stable, suppressive iTregs. These results advance our understanding of the conditions enabling human iTreg generation and may have important implications for the development of adoptive transfer strategies targeting autoimmune and inflammatory diseases.
C1 [Schmidt, Angelika; Eriksson, Matilda; Shang, Ming-Mei; Tegner, Jesper] Karolinska Inst, Dept Med, Ctr Mol Med, Unit Computat Med, Stockholm, Sweden.
   [Schmidt, Angelika; Eriksson, Matilda; Shang, Ming-Mei; Tegner, Jesper] Karolinska Univ Hosp, Stockholm, Sweden.
   [Weyd, Heiko] German Canc Res Ctr, Tumor Immunol Program, Div Immunogenet, Heidelberg, Germany.
RP Schmidt, A (reprint author), Karolinska Inst, Dept Med, Ctr Mol Med, Unit Computat Med, Stockholm, Sweden.; Schmidt, A (reprint author), Karolinska Univ Hosp, Stockholm, Sweden.
EM angelika.schmidt@ki.se
RI Schmidt, Angelika/E-1909-2016; tegner, jesper/R-5095-2017; Schmidt,
   Angelika/J-8773-2019
OI Schmidt, Angelika/0000-0002-1185-3012; tegner,
   jesper/0000-0002-9568-5588; Schmidt, Angelika/0000-0002-1185-3012
FU Marie Curie Intra European Fellowship within the 7th European Community
   Framework Programme (FP7-PEOPLE-IEF); Dr. Ake Olssons Foundation; KI
   Research Foundations; Swedish Research Council; CERIC Linne Center; AFA
   insurance; Stockholm County Council; Torsten Soderberg Foundation
FX This research was supported by a Marie Curie Intra European Fellowship
   within the 7th European Community Framework Programme
   (FP7-PEOPLE-2012-IEF; to AS), Dr. Ake Olssons Foundation (AS), KI
   Research Foundations (AS; JT), Swedish Research Council (JT), CERIC
   Linne Center (JT), AFA insurance (JT), Stockholm County Council (JT),
   and Torsten Soderberg Foundation (JT). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554
   Ahmadzadeh M, 2006, BLOOD, V107, P2409, DOI 10.1182/blood-2005-06-2399
   Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Allan SE, 2008, EUR J IMMUNOL, V38, P3282, DOI 10.1002/eji.200838373
   Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932
   Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338
   Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719
   Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036
   Betts BC, 2014, J LEUKOCYTE BIOL, V95, P205, DOI 10.1189/jlb.0313154
   Beyer M, 2011, NAT IMMUNOL, V12, P898, DOI 10.1038/ni.2084
   Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043
   Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795
   Chen Q, 2011, J IMMUNOL, V186, P6329, DOI 10.4049/jimmunol.1100061
   Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S
   de Vries IJM, 2011, CLIN CANCER RES, V17, P841, DOI 10.1158/1078-0432.CCR-10-2227
   Delacher M, 2014, CURR TOP MICROBIOL I
   Dhamne C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00253
   Di Ianni M, 2011, BLOOD, V117, P3921, DOI 10.1182/blood-2010-10-311894
   Duthoit CT, 2004, J IMMUNOL, V172, P2238, DOI 10.4049/jimmunol.172.4.2238
   Edinger M, 2011, CURR OPIN IMMUNOL, V23, P679, DOI 10.1016/j.coi.2011.06.006
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Fu WX, 2012, NAT IMMUNOL, V13, P972, DOI 10.1038/ni.2420
   Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721
   Gasteiger G, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00179
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   Geiger TL, 2012, HUM IMMUNOL, V73, P232, DOI 10.1016/j.humimm.2011.12.012
   Golovina TN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015868
   Gottschalk RA, 2010, J EXP MED, V207, P1701, DOI 10.1084/jem.20091999
   Gu J, 2014, J IMMUNOL, V193, P3388, DOI 10.4049/jimmunol.1400207
   Haribhai D, 2011, IMMUNITY, V35, P109, DOI 10.1016/j.immuni.2011.03.029
   Haribhai D, 2009, J IMMUNOL, V182, P3461, DOI 10.4049/jimmunol.0802535
   Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477
   Hippen KL, 2011, AM J TRANSPLANT, V11, P1148, DOI 10.1111/j.1600-6143.2011.03558.x
   Hippen KL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001809
   Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409
   Huang YJ, 2014, EUR J IMMUNOL, V44, P460, DOI 10.1002/eji.201343463
   Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474
   Hulsdunker J, 2015, TISSUE ANTIGENS, V85, P2, DOI 10.1111/tan.12497
   Huter EN, 2008, EUR J IMMUNOL, V38, P1814, DOI 10.1002/eji.200838346
   Inaba H, 2008, J IMMUNOL, V181, P3323, DOI 10.4049/jimmunol.181.5.3323
   Inaba H, 2006, INT IMMUNOL, V18, P1043, DOI 10.1093/intimm/dxl038
   Issa F, 2010, TRANSPLANTATION, V90, P1321, DOI 10.1097/TP.0b013e3181ff8772
   Ito R, 2009, TRANSPLANTATION, V87, P1654, DOI 10.1097/TP.0b013e3181a5cb07
   Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011
   Izcue A, 2006, IMMUNOL REV, V212, P256, DOI 10.1111/j.0105-2896.2006.00423.x
   Jhunjhunwala S, 2013, J LEUKOCYTE BIOL, V94, P981, DOI 10.1189/jlb.0312167
   Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772
   Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009
   Kang SG, 2007, J IMMUNOL, V179, P3724, DOI 10.4049/jimmunol.179.6.3724
   Kitagawa Y, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00106
   Koenecke C, 2009, EUR J IMMUNOL, V39, P3091, DOI 10.1002/eji.200939432
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Kopf H, 2007, INT IMMUNOPHARMACOL, V7, P1819, DOI 10.1016/j.intimp.2007.08.027
   Koreth J, 2011, NEW ENGL J MED, V365, P2055, DOI 10.1056/NEJMoa1108188
   Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265
   Lan Q, 2012, J MOL CELL BIOL, V4, P22, DOI 10.1093/jmcb/mjr039
   Lee JH, 2012, EUR J IMMUNOL, V42, P2683, DOI 10.1002/eji.201142317
   Lu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024590
   Lu L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015150
   Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435
   Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610
   Meenu Sharma, 2013, Journal of Current Chemical and Pharmaceutical Sciences, V3, P23
   Merkenschlager M, 2010, J EXP MED, V207, P1347, DOI 10.1084/jem.20101156
   Miyao T, 2012, IMMUNITY, V36, P262, DOI 10.1016/j.immuni.2011.12.012
   Morikawa H, 2014, P NATL ACAD SCI USA, V111, P5289, DOI 10.1073/pnas.1312717110
   Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697
   Ng THS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00129
   Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010
   Oliveira VG, 2011, EUR J IMMUNOL, V41, P1249, DOI 10.1002/eji.201040896
   Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077
   Park J, 2014, MUCOSAL IMMUNOL
   Pere H, 2012, ONCOIMMUNOLOGY, V1, P326, DOI 10.4161/onci.18852
   Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Qian XF, 2011, INT IMMUNOPHARMACOL, V11, P630, DOI 10.1016/j.intimp.2010.11.036
   Sakaguchi S, 2011, METHODS MOL BIOL, V707, P3, DOI 10.1007/978-1-61737-979-6_1
   Samstein RM, 2012, CELL, V150, P29, DOI 10.1016/j.cell.2012.05.031
   Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105
   Schmidt A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002179
   Schmitt EG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00152
   Schmitt EG, 2012, J IMMUNOL, V189, P5638, DOI 10.4049/jimmunol.1200936
   Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668
   Scotta C, 2013, HAEMATOLOGICA, V98, P1291, DOI 10.3324/haematol.2012.074088
   Sela U, 2011, J EXP MED, V208, P2489, DOI 10.1084/jem.20110466
   Semple K, 2011, BLOOD, V117, P3096, DOI 10.1182/blood-2010-08-301275
   Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982
   Shevach EM, 2014, IMMUNOL REV, V259, P88, DOI 10.1111/imr.12160
   Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   Strainic MG, 2013, NAT IMMUNOL, V14, P162, DOI 10.1038/ni.2499
   Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602
   Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473
   Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656
   Trzonkowski P, 2009, CLIN IMMUNOL, V133, P22, DOI 10.1016/j.clim.2009.06.001
   Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Wang J, 2009, J IMMUNOL, V183, P4119, DOI 10.4049/jimmunol.0901065
   Weiss JM, 2012, J EXP MED, V209, P1723, DOI 10.1084/jem.20120914
   Wu DC, 2013, TRANSPLANTATION, V96, P707, DOI 10.1097/TP.0b013e31829fa271
   Yadav M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00232
   Yadav M, 2012, J EXP MED, V209, P1713, DOI 10.1084/jem.20120822
   Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165
   Yamaguchi T, 2013, P NATL ACAD SCI USA, V110, pE2116, DOI 10.1073/pnas.1307185110
   Zhang H, 2005, NAT MED, V11, P1238, DOI 10.1038/nm1312
   Zhang P, 2013, J IMMUNOL, V191, P5291, DOI 10.4049/jimmunol.1301181
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
   Zheng Y, 2008, J IMMUNOL, V181, P1683, DOI 10.4049/jimmunol.181.3.1683
   Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878
   Zorn E, 2006, CLIN CANCER RES, V12, P5265, DOI 10.1158/1078-0432.CCR-06-1417
   Zuniga LA, 2013, IMMUNOL REV, V252, P78, DOI 10.1111/imr.12036
NR 116
TC 37
Z9 39
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 17
PY 2016
VL 11
IS 2
AR e0148474
DI 10.1371/journal.pone.0148474
PG 31
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF3BJ
UT WOS:000371218400036
PM 26886923
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Nguyen, TLM
   Makhlouf, NT
   Anthony, BA
   Teague, RM
   DiPaolo, RJ
AF Nguyen, Thanh-Long M.
   Makhlouf, Nabil T.
   Anthony, Bryan A.
   Teague, Ryan M.
   DiPaolo, Richard J.
TI In Vitro Induced Regulatory T Cells Are Unique from Endogenous
   Regulatory T Cells and Effective at Suppressing Late Stages of Ongoing
   Autoimmunity
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXP3; TGF-BETA; INFECTIOUS TOLERANCE; DENDRITIC
   CELLS; VIVO; ENCEPHALOMYELITIS; DIFFERENTIATION; ACTIVATION; INDUCTION;
   RESPONSES
AB In Strategies to boost the numbers and functions of regulatory T cells (Tregs) are currently being tested as means to treat autoimmunity. While Tregs have been shown to be effective in this role, strategies to manipulate Tregs to effectively suppress later stages of ongoing diseases need to be established. In this study, we evaluated the ability of TGF-beta-induced Tregs (iTregs) specific for the major self-antigen in autoimmune gastritis to suppress established autoimmune gastritis in mice. When transferred into mice during later stages of disease, iTregs demethylated the Foxp3 promoter, maintained Foxp3 expression, and suppressed effector T cell proliferation. More importantly, these iTregs were effective at stopping disease progression. Untreated mice had high numbers of endogenous Tregs (enTregs) but these were unable to stop disease progression. In contrast, iTregs, were found in relatively low numbers in treated mice, yet were effective at stopping disease progression, suggesting qualitative differences in suppressor functions. We identified several inhibitory receptors (LAG-3, PD-1, GARP, and TNFR2), cytokines (TGF-beta 1 and IL12p35), and transcription factors (IRF4 and Tbet) expressed at higher levels by iTregs compared to enTregs isolated form mice with ongoing disease, which likely accounts for superior suppressor ability in this disease model. These data support efforts to use iTregs in therapies to treat establish autoimmunity, and show that iTregs are more effective than enTregs at suppressing inflammation in this disease model.
C1 [Nguyen, Thanh-Long M.; Makhlouf, Nabil T.; Anthony, Bryan A.; Teague, Ryan M.; DiPaolo, Richard J.] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA.
RP DiPaolo, RJ (reprint author), St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63103 USA.
EM rdipaolo@slu.edu
FU RJD: American Cancer Society Research Scholar Grant [12-171-01-LIB]
FX RJD: American Cancer Society Research Scholar Grant 12-171-01-LIB. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554
   Alderuccio F, 1995, AUTOIMMUNITY, V21, P215, DOI 10.3109/08916939509008018
   Andersson J, 2008, J EXP MED, V205, P1975, DOI 10.1084/jem.20080308
   Bailey-Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016
   Bennett CL, 2001, IMMUNOGENETICS, V53, P435, DOI 10.1007/s002510100358
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Chattopadhyay G, 2013, J IMMUNOL, V191, P5875, DOI 10.4049/jimmunol.1301693
   Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702
   Chen Q, 2011, J IMMUNOL, V186, P6329, DOI 10.4049/jimmunol.1100061
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Chen X, 2010, EUR J IMMUNOL, V40, P1099, DOI 10.1002/eji.200940022
   Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306
   CORREA P, 1988, CANCER RES, V48, P3554
   Deknuydt F, 2009, CLIN IMMUNOL, V131, P298, DOI 10.1016/j.clim.2008.12.008
   DiPaolo RJ, 2007, J IMMUNOL, V179, P4685, DOI 10.4049/jimmunol.179.7.4685
   DiPaolo RJ, 2005, J IMMUNOL, V175, P7135, DOI 10.4049/jimmunol.175.11.7135
   Fantini MC, 2006, GUT, V55, P671, DOI 10.1136/gut.2005.072801
   Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2003, NAT IMMUNOL
   Fu WX, 2012, NAT IMMUNOL, V13, P972, DOI 10.1038/ni.2420
   Godebu E, 2008, J IMMUNOL, V181, P1798, DOI 10.4049/jimmunol.181.3.1798
   Haribhai D, 2011, IMMUNITY, V35, P109, DOI 10.1016/j.immuni.2011.03.029
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623
   Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428
   Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Lan Q, 2012, J MOL CELL BIOL, V4, P22, DOI 10.1093/jmcb/mjr039
   Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737
   Liang BT, 2008, J IMMUNOL, V180, P5916, DOI 10.4049/jimmunol.180.9.5916
   Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445
   McHugh RS, 2001, EUR J IMMUNOL, V31, P2094, DOI 10.1002/1521-4141(200107)31:7<2094::AID-IMMU2094>3.0.CO;2-S
   Nguyen TLM, 2011, J IMMUNOL, V187, P1745, DOI 10.4049/jimmunol.1004112
   Nguyen TL, 2013, CANC RES
   O'Connor RA, 2010, J IMMUNOL, V185, P7235, DOI 10.4049/jimmunol.1001551
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Rogers AB, 2005, CANCER RES, V65, P10709, DOI 10.1158/008-5472.CAN-05-1846
   Schmitt EG, 2012, J IMMUNOL, V189, P5638, DOI 10.4049/jimmunol.1200936
   Sehrawat S, 2008, J VIROL, V82, P6838, DOI 10.1128/JVI.00697-08
   Selvaraj RK, 2008, J IMMUNOL, V180, P2830, DOI 10.4049/jimmunol.180.5.2830
   SELVARAJ RK, 2007, J IMMUNOL, V179
   Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567
   van Driel IR, 2005, CURR OPIN IMMUNOL, V17, P570, DOI 10.1016/j.coi.2005.09.016
   Wang CH, 2010, J NEUROSCI RES, V88, P7, DOI 10.1002/jnr.22181
   Wang R, 2012, MOL BIOL CELL, V23, P1129, DOI 10.1091/mbc.E11-12-1018
   Weber SE, 2006, J IMMUNOL, V176, P4730, DOI 10.4049/jimmunol.176.8.4730
   Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707
   Yadav M, 2012, J EXP MED, V209, P1713, DOI 10.1084/jem.20120822
   Zhang H, 2010, J IMMUNOL, V184, P6629, DOI 10.4049/jimmunol.0904044
   Zheng SG, 2004, J IMMUNOL, V172, P1531, DOI 10.4049/jimmunol.172.3.1531
   Zheng SG, 2008, J IMMUNOL, V180, P7112, DOI 10.4049/jimmunol.180.11.7112
   Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674
   Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774
NR 54
TC 10
Z9 10
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2014
VL 9
IS 8
AR e104698
DI 10.1371/journal.pone.0104698
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN9BM
UT WOS:000340900600079
PM 25119105
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Schreiber, L
   Pietzsch, B
   Floess, S
   Farah, C
   Jansch, L
   Schmitz, I
   Huehn, J
AF Schreiber, Lisa
   Pietzsch, Beate
   Floess, Stefan
   Farah, Carla
   Jaensch, Lothar
   Schmitz, Ingo
   Huehn, Jochen
TI The Treg-Specific Demethylated Region Stabilizes Foxp3 Expression
   Independently of NF-kappa B Signaling
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; C-REL; TRANSCRIPTION FACTOR; GENE-EXPRESSION; DNA
   METHYLATION; LINEAGE; ACTIVATION; INDUCTION; CARMA1; STIMULATION
AB Regulatory T cells (Tregs) obtain immunosuppressive capacity by the upregulation of forkhead box protein 3 (Foxp3), and persistent expression of this transcription factor is required to maintain their immune regulatory function and ensure immune homeostasis. Stable Foxp3 expression is achieved through epigenetic modification of the Treg-specific demethylated region (TSDR), an evolutionarily conserved non-coding element within the Foxp3 gene locus. Here, we present molecular data suggesting that TSDR enhancer activity is restricted to T cells and cannot be induced in other immune cells such as macrophages or B cells. Since NF-kappa B signaling has been reported to be instrumental to induce Foxp3 expression during Treg development, we analyzed how NF-kappa B factors are involved in the molecular regulation of the TSDR. Unexpectedly, we neither observed transcriptional activity of a previously postulated NF-kappa B binding site within the TSDR nor did the entire TSDR show any transcriptional responsiveness to NF-kappa B activation at all. Finally, the NF-kappa B subunit c-Rel revealed to be dispensable for epigenetic imprinting of sustained Foxp3 expression by TSDR demethylation. In conclusion, we show that NF-kappa B signaling is not substantially involved in TSDR-mediated stabilization of Foxp3 expression in Tregs.
C1 [Schreiber, Lisa; Pietzsch, Beate; Floess, Stefan; Farah, Carla; Huehn, Jochen] Helmholtz Ctr Infect Res, Dept Expt Immunol, Braunschweig, Germany.
   [Jaensch, Lothar] Helmholtz Ctr Infect Res, Res Grp Cellular Prote, Braunschweig, Germany.
   [Schmitz, Ingo] Helmholtz Ctr Infect Res, Res Grp Syst Oriented Immunol & Inflammat Res, Braunschweig, Germany.
   [Schmitz, Ingo] Otto Von Guericke Univ, Inst Mol & Clin Immunol, Magdeburg, Germany.
RP Huehn, J (reprint author), Helmholtz Ctr Infect Res, Dept Expt Immunol, Braunschweig, Germany.
EM Jochen.Huehn@helmholtz-hzi.de
RI Schmitz, Ingo/G-2093-2013
OI Schmitz, Ingo/0000-0002-5360-0419
FU German Research Foundation [SFB738, SFB854]
FX This work was supported by the German Research Foundation (SFB738 and
   SFB854). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Barnes MJ, 2009, PLOS BIOL, V7, P513, DOI 10.1371/journal.pbio.1000051
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156
   Deenick EK, 2010, EUR J IMMUNOL, V40, P677, DOI 10.1002/eji.201040298
   DiDonato J, 1996, MOL CELL BIOL, V16, P1295
   Eckerstorfer P, 2010, MOL IMMUNOL, V47, P2094, DOI 10.1016/j.molimm.2010.04.002
   Ehlers M, 2003, J IMMUNOL, V171, P3594, DOI 10.4049/jimmunol.171.7.3594
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543
   Grigoriadis G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026851
   Guckel E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020003
   Gupta S, 2008, MOL IMMUNOL
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13
   He HQ, 2011, IMMUNOBIOLOGY, V216, P678, DOI 10.1016/j.imbio.2010.11.002
   Hori S, 2010, EUR J IMMUNOL, V40, P664, DOI 10.1002/eji.201040372
   Hsieh CS, 2009, IMMUNITY, V31, P852, DOI 10.1016/j.immuni.2009.11.006
   Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474
   Isomura I, 2009, J EXP MED, V206, P3001, DOI 10.1084/jem.20091411
   Josefowicz SZ, 2009, J IMMUNOL, V182, P6648, DOI 10.4049/jimmunol.0803320
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   KIM KJ, 1979, J IMMUNOL, V122, P549
   Leslie M, 2011, SCIENCE, V332, P1020, DOI 10.1126/science.332.6033.1020
   Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022
   Medoff BD, 2009, EUR J IMMUNOL, V39, P78, DOI 10.1002/eji.200838734
   Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860
   Miyao T, 2012, IMMUNITY, V36, P262, DOI 10.1016/j.immuni.2011.12.012
   Molinero LL, 2009, J IMMUNOL, V182, P6736, DOI 10.4049/jimmunol.0900498
   Mouly E, 2010, J EXP MED, V207, P2113, DOI 10.1084/jem.20092153
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Polansky JK, 2010, J MOL MED, V88, P1029, DOI 10.1007/s00109-010-0642-1
   Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724
   RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0
   Ruan QG, 2009, IMMUNITY, V31, P932, DOI 10.1016/j.immuni.2009.10.006
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Schmidt-Supprian M, 2004, P NATL ACAD SCI USA, V101, P4566, DOI 10.1073/pnas.0400885101
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schulze-Luehrmann J, 2006, IMMUNITY, V25, P701, DOI 10.1016/j.immuni.2006.10.010
   Schuster M, 2012, IMMUNITY, V37, P998, DOI 10.1016/j.immuni.2012.08.023
   Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177
   Toker A, 2013, J IMMUNOL
   Toker A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001783
   Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y
   Vang KB, 2010, J IMMUNOL, V184, P4074, DOI 10.4049/jimmunol.0903933
   Visekruna A, 2010, EUR J IMMUNOL, V40, P671, DOI 10.1002/eji.200940260
   VIVIER E, 1993, EUR J IMMUNOL, V23, P1872, DOI 10.1002/eji.1830230821
   Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437
   Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
   Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747
NR 54
TC 12
Z9 12
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 5
PY 2014
VL 9
IS 2
AR e88318
DI 10.1371/journal.pone.0088318
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA1AT
UT WOS:000330829200174
PM 24505473
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Takasato, F
   Morita, R
   Schichita, T
   Sekiya, T
   Morikawa, Y
   Kuroda, T
   Niimi, M
   Yoshimura, A
AF Takasato, Fumika
   Morita, Rimpei
   Schichita, Takashi
   Sekiya, Takashi
   Morikawa, Yasuhide
   Kuroda, Tatsuo
   Niimi, Masanori
   Yoshimura, Akihiko
TI Prevention of Allogeneic Cardiac Graft Rejection by Transfer of Ex Vivo
   Expanded Antigen-Specific Regulatory T-Cells
SO PLOS ONE
LA English
DT Article
ID TOLEROGENIC DENDRITIC CELLS; TGF-BETA; INTRATRACHEAL DELIVERY;
   TRANSPLANT TOLERANCE; FOXP3 EXPRESSION; CUTTING EDGE; IN-VIVO;
   INDUCTION; MICE; SUPPRESSION
AB The rate of graft survival has dramatically increased using calcineurin inhibitors, however chronic graft rejection and risk of infection are difficult to manage. Induction of allograft-specific regulatory T-cells (Tregs) is considered an ideal way to achieve long-term tolerance for allografts. However, efficient in vitro methods for developing allograft-specific Tregs which is applicable to MHC full-mismatched cardiac transplant models have not been established. We compared antigen-nonspecific polyclonal-induced Tregs (iTregs) as well as antigen-specific iTregs and thymus-derived Tregs (nTregs) that were expanded via direct and indirect pathways. We found that iTregs induced via the indirect pathway had the greatest ability to prolong graft survival and suppress angiitis. Antigen-specific iTregs generated ex vivo via both direct and indirect pathways using dendritic cells from F1 mice also induced long-term engraftment without using MHC peptides. In antigen-specific Treg transferred models, activation of dendritic cells and allograft-specific CTL generation were suppressed. The present study demonstrated the potential of ex vivo antigen-specific Treg expansion for clinical cell-based therapeutic approaches to induce lifelong immunological tolerance for allogeneic cardiac transplants.
C1 [Takasato, Fumika; Morita, Rimpei; Schichita, Takashi; Sekiya, Takashi; Yoshimura, Akihiko] Keio Univ, Dept Microbiol & Immunol, Sch Med, Tokyo, Japan.
   [Takasato, Fumika; Kuroda, Tatsuo] Keio Univ, Sch Med, Dept Pediat Surg, Tokyo, Japan.
   [Morikawa, Yasuhide] Int Univ Med Welf Hosp, Dept Pediat Surg, Nasushiobara, Tochigi, Japan.
   [Niimi, Masanori] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan.
   [Takasato, Fumika; Morita, Rimpei; Schichita, Takashi; Sekiya, Takashi; Yoshimura, Akihiko] Japan Sci & Technol Agcy, CREST, Tokyo, Japan.
RP Yoshimura, A (reprint author), Keio Univ, Dept Microbiol & Immunol, Sch Med, Tokyo, Japan.
EM yoshimura@a6.keio.jp
RI Yoshimura, Akihiko/K-5515-2013
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Japan Society of the Promotion of Science; Takeda Science Foundation;
   Uehara Memorial Foundation; Kanae Foundation for the Promotion of
   Medical Science; SENSHIN Medical Research Foundation; Astellas
   Foundation for Research on Metabolic Disorders; Mochida Memorial
   Foundation
FX This work was supported by special grants-in-aid from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan, the Japan
   Society of the Promotion of Science, the Takeda Science Foundation, the
   Uehara Memorial Foundation, Kanae Foundation for the Promotion of
   Medical Science, SENSHIN Medical Research Foundation, Astellas
   Foundation for Research on Metabolic Disorders, and the Mochida Memorial
   Foundation. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Akiyama Y, 2002, HUM IMMUNOL, V63, P888, DOI 10.1016/S0198-8859(02)00456-1
   Aramaki O, 2003, TRANSPLANTATION, V76, P1305, DOI 10.1097/01.TP.0000084398.10572.C6
   Brennan TV, 2009, AM J TRANSPLANT, V9, P709, DOI 10.1111/j.1600-6143.2009.02578.x
   Burrell BE, 2012, J IMMUNOL, V189, P4705, DOI 10.4049/jimmunol.1202027
   Cervera C, 2011, TRANSPL INFECT DIS, V13, P598, DOI 10.1111/j.1399-3062.2011.00646.x
   Chai JG, 2008, J IMMUNOL, V180, P858, DOI 10.4049/jimmunol.180.2.858
   Fernandez MA, 2008, J IMMUNOL, V180, P1556, DOI 10.4049/jimmunol.180.3.1556
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Gupta S, 2011, TRANSPLANTATION, V91, pE65, DOI 10.1097/TP.0b013e3182157d44
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Ichiyama K, 2011, IMMUNITY, V34, P741, DOI 10.1016/j.immuni.2011.02.021
   Joffre O, 2008, NAT MED, V14, P88, DOI 10.1038/nm1688
   Jones ND, 2010, EUR J IMMUNOL, V40, P3107, DOI 10.1002/eji.201040671
   Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394
   Kang SM, 2007, AM J TRANSPLANT, V7, P1457, DOI 10.1111/j.1600-6143.2007.01829.x
   Kinter A, 2007, P NATL ACAD SCI USA, V104, P3390, DOI 10.1073/pnas.06114234104
   Koenecke C, 2009, EUR J IMMUNOL, V39, P3091, DOI 10.1002/eji.200939432
   Koga K, 2009, IMMUNITY, V30, P372, DOI 10.1016/j.immuni.2008.12.021
   Latek R, 2009, TRANSPLANTATION, V87, P926, DOI 10.1097/TP.0b013e31819b5a58
   Li M, 2008, INT IMMUNOL, V20, P285, DOI 10.1093/intimm/dxm142
   Lu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024590
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132
   Niimi M, 2001, J HEART LUNG TRANSPL, V20, P1123, DOI 10.1016/S1053-2498(01)00309-6
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Sampaio MS, 2012, TRANSPLANTATION, V94, P990, DOI 10.1097/TP.0b013e318270bc7b
   Sekiya T, 2013, NAT IMMUNOL, V14, P230, DOI 10.1038/ni.2520
   Sela U, 2011, J EXP MED, V208, P2489, DOI 10.1084/jem.20110466
   Shevach EM, 2008, J CLIN IMMUNOL, V28, P640, DOI 10.1007/s10875-008-9240-1
   Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749
   Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823
   Takahashi R, 2011, J EXP MED, V208, P2055, DOI 10.1084/jem.20110428
   Takimoto T, 2010, J IMMUNOL, V185, P842, DOI 10.4049/jimmunol.0904100
   Tamiya T, 2013, J IMMUNOL, V191, P2360, DOI 10.4049/jimmunol.1301276
   Taner T, 2005, AM J TRANSPLANT, V5, P228, DOI 10.1046/j.1600-6143.2004.00673.x
   Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572
   Tarbell KV, 2007, J EXP MED, V204, P191, DOI 10.1084/jem.20061631
   van Kooten C, 2011, TRANSPLANTATION, V91, P2, DOI 10.1097/TP.0b013e31820263b3
   van Maurik A, 2002, J IMMUNOL, V169, P5401
   Waldmann H, 2008, NAT IMMUNOL, V9, P1001, DOI 10.1038/ni0908-1001
   Woltman AM, 2006, AM J TRANSPLANT, V6, P2580, DOI 10.1111/j.1600-6143.2006.01520.x
   Wood KJ, 2011, TRANSPL P, V43, P2135, DOI 10.1016/j.transproceed.2011.06.050
   Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027
   Zhang XS, 2008, CLIN IMMUNOL, V127, P313, DOI 10.1016/j.clim.2008.01.013
   Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018
   Zhou XH, 2010, J IMMUNOL, V185, P2675, DOI 10.4049/jimmunol.1000598
   Zuppan CW, 2009, J HEART LUNG TRANSPL, V28, P579, DOI 10.1016/j.healun.2009.02.012
NR 47
TC 14
Z9 15
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 3
PY 2014
VL 9
IS 2
AR e87722
DI 10.1371/journal.pone.0087722
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 302TD
UT WOS:000330626900108
PM 24498362
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Zhang, XL
   Li, XC
   Xiao, X
   Sun, R
   Tian, ZG
   Wei, HM
AF Zhang, Xiaolong
   Li, Xian Chang
   Xiao, Xiang
   Sun, Rui
   Tian, Zhigang
   Wei, Haiming
TI CD4(+)CD62L(+) Central Memory T Cells Can Be Converted to Foxp3(+) T
   Cells
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXP3; B-VIRUS INFECTION; TGF-BETA; IN-VIVO; IMMUNE
   PATHOLOGY; REGULATORY CELLS; RETINOIC ACID; EXPRESSION; SUPPRESSION;
   INDUCTION
AB The peripheral Foxp3(+) Treg pool consists of naturally arising Treg (nTreg) and adaptive Treg cells (iTreg). It is well known that naive CD4(+) T cells can be readily converted to Foxp3(+) iTreg in vitro, and memory CD4(+) T cells are resistant to conversion. In this study, we investigated the induction of Foxp3(+) T cells from various CD4(+) T-cell subsets in human peripheral blood. Though naive CD4(+) T cells were readily converted to Foxp3(+) T cells with TGF-beta and IL-2 treatment in vitro, such Foxp3(+) T cells did not express the memory marker CD45RO as do Foxp3(+) T cells induced in the peripheral blood of Hepatitis B Virus (HBV) patients. Interestingly, a subset of human memory CD4(+) T cells, defined as CD62L(+) central memory T cells, could be induced by TGF-beta to differentiate into Foxp3(+) T cells. It is well known that Foxp3(+) T cells derived from human CD4(+)CD25(-) T cells in vitro are lack suppressive functions. Our data about the suppressive functions of CD4(+)CD62L(+) central memory T cell-derived Foxp3(+) T cells support this conception, and an epigenetic analysis of these cells showed a similar methylation pattern in the FOXP3 Treg-specific demethylated region as the naive CD4(+) T cell-derived Foxp3(+) T cells. But further research showed that mouse CD4(+) central memory T cells also could be induced to differentiate into Foxp3(+) T cells, such Foxp3(+) T cells could suppress the proliferation of effector T cells. Thus, our study identified CD4(+)CD62L(+) central memory T cells as a novel potential source of iTreg.
C1 [Zhang, Xiaolong; Sun, Rui; Tian, Zhigang; Wei, Haiming] Univ Sci & Technol China, Inst Immunol, Sch Life Sci, Hefei 230026, Anhui, Peoples R China.
   [Li, Xian Chang; Xiao, Xiang] Brigham & Womens Hosp, Transplant Res Ctr, Boston, MA 02115 USA.
   [Li, Xian Chang; Xiao, Xiang] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
   [Sun, Rui; Tian, Zhigang; Wei, Haiming] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.
RP Tian, ZG (reprint author), Univ Sci & Technol China, Inst Immunol, Sch Life Sci, Hefei 230026, Anhui, Peoples R China.
EM tzg@ustc.edu.cn; ustcwhm@ustc.edu.cn
RI Tian, Zhigang/J-3512-2013
OI Li, Xian Chang/0000-0002-5981-2762; xiao, xiang/0000-0001-6644-6118
FU Ministry of Science & Technology of China [2009CB522403, 2012CB519004];
   Natural Science Foundation of China [31021061]
FX This work was supported by Ministry of Science & Technology of China
   (973 Basic Science Project 2009CB522403, 2012CB519004) and Natural
   Science Foundation of China (#31021061). This work was supported by
   Ministry of Science & Technology of China (973 Basic Science Project
   2009CB522403, 2012CB519004) and Natural Science Foundation of China
   (#31021061). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Antunes I, 2008, IMMUNITY, V29, P782, DOI 10.1016/j.immuni.2008.09.016
   Antunes I, 2010, J VIROL, V84, P12564, DOI 10.1128/JVI.01559-10
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Clarke SL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000129
   Daniel V, 2008, TRANSPL INT, V21, P646, DOI 10.1111/j.1432-2277.2008.00662.x
   Daniel V, 2011, HUM IMMUNOL, V72, P699, DOI 10.1016/j.humimm.2011.05.020
   Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677
   de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002
   Dejaco C, 2006, EUR J IMMUNOL, V36, P245, DOI [10.1002/eji.200535193, 10.1002/eji.200535651]
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Franceschini D, 2009, J CLIN INVEST, V119, P551, DOI 10.1172/JCI36604
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   Hill JA, 2008, IMMUNITY, V29, P758, DOI 10.1016/j.immuni.2008.09.018
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Janson PCJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001612
   Kim BS, 2010, P NATL ACAD SCI USA, V107, P8742, DOI 10.1073/pnas.0911756107
   Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265
   Li XC, 2010, NAT REV NEPHROL, V6, P577, DOI 10.1038/nrneph.2010.101
   Liu J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013267
   McMahon BJ, 2009, HEPATOLOGY, V49, pS45, DOI 10.1002/hep.22898
   Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016
   Nagar M, 2008, INT IMMUNOL, V20, P1041, DOI 10.1093/intimm/dxn062
   Peng GP, 2008, IMMUNOLOGY, V123, P57, DOI 10.1111/j.1365-2567.2007.02691.x
   Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014
   Presicce P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028118
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Schramm C, 2004, INT IMMUNOL, V16, P1241, DOI 10.1093/intimm/dxh126
   Seddiki N, 2006, BLOOD, V107, P2830, DOI 10.1182/blood-2005-06-2403
   Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010
   Singh A, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030947, 10.1371/journal.pone.0044728]
   Stockinger B, 2004, SEMIN IMMUNOL, V16, P295, DOI 10.1016/j.smim.2004.08.010
   Stockinger B, 2006, IMMUNOL REV, V211, P39, DOI 10.1111/j.0105-2896.2006.00381.x
   Stoop JN, 2005, HEPATOLOGY, V41, P771, DOI 10.1002/hep.20649
   Sun C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002594
   Szajnik M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011469
   Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656
   Vukmanovic-Stejic M, 2008, J CLIN INVEST, V118, P3639, DOI 10.1172/JCI35834
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Wang J, 2009, J IMMUNOL, V183, P4119, DOI 10.4049/jimmunol.0901065
   Wang WS, 2009, INT IMMUNOL, V21, P1065, DOI 10.1093/intimm/dxp072
   Wing K, 2002, IMMUNOLOGY, V106, P190, DOI 10.1046/j.1365-2567.2002.01412.x
   Wing K, 2006, INT IMMUNOL, V18, P991, DOI 10.1093/intimm/dxl044
   Xiao X, 2008, J IMMUNOL, V181, P3193, DOI 10.4049/jimmunol.181.5.3193
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
NR 51
TC 15
Z9 15
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 14
PY 2013
VL 8
IS 10
AR e77322
DI 10.1371/journal.pone.0077322
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 237RD
UT WOS:000325887300076
PM 24155942
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Yoshimoto, M
   Yoder, MC
   Guevara, P
   Adkins, B
AF Yoshimoto, Momoko
   Yoder, Mervin C.
   Guevara, Patricia
   Adkins, Becky
TI The Murine Th2 Locus Undergoes Epigenetic Modification in the Thymus
   during Fetal and Postnatal Ontogeny
SO PLOS ONE
LA English
DT Article
ID LYMPHOCYTE PRECURSOR CELLS; DISTAL REGULATORY ELEMENTS; HEMATOPOIETIC
   STEM-CELLS; PRIMORDIAL GERM-CELLS; T-CELLS; DNA METHYLATION; IL-4 GENE;
   LINEAGE COMMITMENT; CYCLIC RENEWAL; IMMUNE-SYSTEM
AB Epigenetic modifications play a central role in the differentiation and function of immune cells in adult animals. Developmentally regulated epigenetic patterns also appear to contribute to the ontogeny of the immune system. We show here that the epigenetic profile of the T-helper (Th) 2 locus undergoes changes in T lineage cells beginning in mid-gestation and extending throughout the first week of life. In particular, regulatory regions of the Th2 locus are largely methylated at CpG residues among fetal liver common lymphoid progenitor cells. The locus subsequently becomes highly hypomethylated among the downstream progeny of these cells within the fetal thymus. This hypomethylated state is preserved until birth when the locus becomes rapidly re-methylated, achieving adult-like status by 3-6 days post birth. Notably, the capacity for rapid, high level Th2 cytokine production is lost in parallel with this re-methylation. In vitro organ culture and in vivo transplantation experiments indicate that signals from the adult environment are required to achieve the postnatal methylated state. Together, these findings indicate that the Th2 bias of neonates may be conferred, in part, by an epigenetic profile inherited from fetal life. However, the fetal program is rapidly terminated post birth by the development of signals leading to the acquisition of adult-like epigenetic patterns.
C1 [Yoshimoto, Momoko; Yoder, Mervin C.] Indiana Univ Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN USA.
   [Guevara, Patricia; Adkins, Becky] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
RP Adkins, B (reprint author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
EM radkins@med.miami.edu
RI Yoshimoto, Momoko/N-4238-2014
OI Yoshimoto, Momoko/0000-0002-7272-6682
FU National Institute of Allergy and Infectious Diseases [AI044923,
   AI080759]
FX This work was supported by grants from the National Institute of Allergy
   and Infectious Diseases AI044923 (B.A) and AI080759 (M.C.Y.). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ADKINS B, 1994, J IMMUNOL, V153, P5359
   Adkins B, 2003, J IMMUNOL, V171, P5157, DOI 10.4049/jimmunol.171.10.5157
   Adkins B, 2006, Haematol Rep, V2, P9
   Adkins B, 2000, Int Rev Immunol, V19, P157, DOI 10.3109/08830180009088503
   Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821
   Aoki K, 2009, J IMMUNOL, V182, P7698, DOI 10.4049/jimmunol.0801643
   BENDELAC A, 1995, CURR OPIN IMMUNOL, V7, P367, DOI 10.1016/0952-7915(95)80112-X
   Benlagha K, 2002, SCIENCE, V296, P553, DOI 10.1126/science.1069017
   Bhandoola A, 2007, IMMUNITY, V26, P678, DOI 10.1016/j.immuni.2007.05.009
   CALVERT JE, 1983, J IMMUNOL, V131, P1693
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   COLTEY M, 1989, J EXP MED, V170, P543, DOI 10.1084/jem.170.2.543
   COLTEY M, 1987, CELL DIFFER DEV, V22, P71, DOI 10.1016/0045-6039(87)90414-3
   Fadel S, 2000, Int Rev Immunol, V19, P173, DOI 10.3109/08830180009088504
   Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Grogan JL, 2003, J IMMUNOL, V171, P6672, DOI 10.4049/jimmunol.171.12.6672
   Guo LY, 2002, P NATL ACAD SCI USA, V99, P10623, DOI 10.1073/pnas.162360199
   Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714
   Hammond K, 1998, INT IMMUNOL, V10, P1491, DOI 10.1093/intimm/10.10.1491
   Ikawa T, 2004, BLOOD, V103, P530, DOI 10.1182/blood-2003-06-1797
   JOTEREAU F, 1987, J IMMUNOL, V138, P1026
   JOTEREAU FV, 1982, J IMMUNOL, V129, P1869
   Kawamoto H, 2000, IMMUNITY, V12, P441, DOI 10.1016/S1074-7613(00)80196-X
   Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X
   Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X
   Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136
   MACDONALD HR, 1995, J EXP MED, V182, P633, DOI 10.1084/jem.182.3.633
   Makar KW, 2003, NAT IMMUNOL, V4, P1183, DOI 10.1038/ni1004
   Martino D., 2012, GENES IMMUN
   Mold JE, 2010, SCIENCE, V330, P1695, DOI 10.1126/science.1196509
   Pellicci DG, 2002, J EXP MED, V195, P835, DOI 10.1084/jem.20011544
   Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829
   PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189
   Prescott SL, 1998, J IMMUNOL, V160, P4730
   Rhodes KE, 2008, CELL STEM CELL, V2, P252, DOI 10.1016/j.stem.2008.01.001
   Ribeiro-do-Couto LM, 2001, EUR J IMMUNOL, V31, P3394, DOI 10.1002/1521-4141(200111)31:11<3394::AID-IMMU3394>3.0.CO;2-B
   Rose S, 2007, J IMMUNOL, V178, P2667, DOI 10.4049/jimmunol.178.5.2667
   Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0
   Schoenborn JR, 2007, NAT IMMUNOL, V8, P732, DOI 10.1038/ni1474
   Seki Y, 2007, DEVELOPMENT, V134, P2627, DOI 10.1242/dev.005611
   Siegrist C A, 2000, Int Rev Immunol, V19, P195, DOI 10.3109/08830180009088505
   Tykocinski LO, 2005, J BIOL CHEM, V280, P28177, DOI 10.1074/jbc.M502038200
   Upham JW, 2006, INFECT IMMUN, V74, P1106, DOI 10.1128/IAI.74.2.1106-1112.2006
   Webster RB, 2007, J BIOL CHEM, V282, P700, DOI 10.1074/jbc.M609501200
   Wilson CB, 2005, SEMIN IMMUNOL, V17, P105, DOI 10.1016/j.smim.2005.01.005
   Wilson CB, 2009, NAT REV IMMUNOL, V9, P91, DOI 10.1038/nri2487
   Yoshimoto M, 2012, BLOOD, V119, P5706, DOI 10.1182/blood-2011-12-397489
NR 48
TC 9
Z9 9
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 15
PY 2013
VL 8
IS 1
AR e51587
DI 10.1371/journal.pone.0051587
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 086SQ
UT WOS:000314707700005
PM 23335954
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Schwarzer, A
   Wolf, B
   Fisher, JL
   Schwaab, T
   Olek, S
   Baron, U
   Tomlinson, CR
   Seigne, JD
   Crosby, NA
   Gui, J
   Hampton, TH
   Fadul, CE
   Heaney, JA
   Ernstoff, MS
AF Schwarzer, Adrian
   Wolf, Benita
   Fisher, Jan L.
   Schwaab, Thomas
   Olek, Sven
   Baron, Udo
   Tomlinson, Craig R.
   Seigne, John D.
   Crosby, Nancy A.
   Gui, Jiang
   Hampton, Thomas H.
   Fadul, Camilo E.
   Heaney, John A.
   Ernstoff, Marc S.
TI Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell
   Carcinoma (mRCC) Patients Undergoing DC-Vaccination and Cytokine-Therapy
SO PLOS ONE
LA English
DT Article
ID HIGH-DOSE INTERLEUKIN-2; PERIPHERAL-BLOOD; FOXP3 EXPRESSION;
   IMMUNOTHERAPY; MELANOMA; TRIAL
AB Purpose: To evaluate CD4(+)CD25(+)FOXP3(+) T regulatory cells (T-REG) and associated immune-regulatory pathways in peripheral blood lymphocytes (PBL) of metastatic renal cell carcinoma (mRCC) patients and healthy volunteers. We subsequently investigated the effects of immunotherapy on circulating T-REG combining an extensive phenotype examination, DNA methylation analysis and global transcriptome analysis.
   Design: Eighteen patients with mRCC and twelve volunteers (controls) were available for analysis. T-REG phenotype was examined using flow cytometry (FCM). T-REG were also quantified by analyzing the epigenetic status of the FOXP3 locus using methylation specific PCR. As a third approach, RNA of the PBL was hybridized to Affymetrix GeneChip Human Gene 1.0 ST Arrays and the gene signatures were explored using pathway analysis.
   Results: We observed higher numbers of T-REG in pre-treatment PBL of mRCC patients compared to controls. A significant increase in T-REG was detected in all mRCC patients after the two cycles of immunotherapy. The expansion of T-REG was significantly higher in non-responders than in responding patients. Methylation specific PCR confirmed the FCM data and circumvented the variability and subjectivity of the FCM method. Gene Set Enrichment Analysis (GSEA) of the microarray data showed significant enrichment of FOXP3 target genes, CTLA-4 and TGF-beta associated pathways in the patient cohort.
   Conclusion: Immune monitoring of the peripheral blood and tumor tissue is important for a wide range of diseases and treatment strategies. Adoption of methodology for quantifying TREG with the least variability and subjectivity will enhance the ability to compare and interpret findings across studies.
C1 [Schwarzer, Adrian; Wolf, Benita; Fisher, Jan L.; Schwaab, Thomas; Crosby, Nancy A.; Fadul, Camilo E.; Ernstoff, Marc S.] Geisel Sch Med Dartmouth, Med Oncol Immunotherapy Grp, Hanover, NH USA.
   [Fisher, Jan L.; Crosby, Nancy A.; Fadul, Camilo E.; Ernstoff, Marc S.] Geisel Sch Med Dartmouth, Sect Hematol Oncol, Hanover, NH USA.
   [Olek, Sven; Baron, Udo] Epiontis GmbH, Berlin, Germany.
   [Tomlinson, Craig R.; Hampton, Thomas H.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA.
   [Seigne, John D.; Heaney, John A.] Geisel Sch Med Dartmouth, Urol Sect, Dept Surg, Hanover, NH USA.
   [Gui, Jiang] Geisel Sch Med Dartmouth, Sect Biostat & Epidemiol, Dept Family & Community Med, Hanover, NH USA.
   [Fadul, Camilo E.; Ernstoff, Marc S.] Geisel Sch Med Dartmouth, Immunotherapy Program, Hanover, NH USA.
   [Fadul, Camilo E.] Geisel Sch Med Dartmouth, Dept Neurol, Hanover, NH USA.
RP Ernstoff, MS (reprint author), Geisel Sch Med Dartmouth, Med Oncol Immunotherapy Grp, Hanover, NH USA.
EM Marc.S.Ernstoff@Hitchcock.ORG
RI Tomlinson, Craig/F-1319-2017
OI Wolf, Benita/0000-0001-5673-4239; Baron, Udo/0000-0001-7432-3601;
   Hampton, Thomas/0000-0003-0543-402X
FU NIH [RO1 CA095648, P20RR016437, P20GM103413, P30CA023108, P42ES007373];
   Berlex, Inc. [D0238]
FX This work was supported by grants from the NIH (RO1 CA095648,
   P20RR016437, P20GM103413, P30CA023108 and P42ES007373) and Berlex, Inc.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; Sven Olek and
   Udo Baron work at Epiontis who did contract testing for this study under
   a collaborative agreement. The authors received funding from Berlex,
   Inc. for the clinical trial (Protocol D0238) from which patient samples
   reported on in this paper originated. This does not alter the authors'
   adherence to all PLOS ONE policies on sharing data and materials.
CR Ahmadzadeh M, 2006, BLOOD, V107, P2409, DOI 10.1182/blood-2005-06-2399
   ATKINS MB, 1993, J CLIN ONCOL, V11, P661, DOI 10.1200/JCO.1993.11.4.661
   Atzpodien J, 2004, J CLIN ONCOL, V22, P1188, DOI 10.1200/JCO.2004.06.155
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Bennett CL, 2001, NAT GENET, V27, P20
   Cesana GC, 2006, J CLIN ONCOL, V24, P1169, DOI 10.1200/JCO.2005.03.6830
   de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jacobs JFM, 2012, LANCET ONCOL, V13, pE32, DOI 10.1016/S1470-2045(11)70155-3
   Jensen HK, 2009, CLIN CANCER RES, V15, P1052, DOI 10.1158/1078-0432.CCR-08-1296
   Jiang Z, 2007, BIOINFORMATICS, V23, P306, DOI 10.1093/bioinformatics/btl599
   Kauffmann A, 2009, BIOINFORMATICS, V25, P2092, DOI 10.1093/bioinformatics/btp354
   Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756
   Motzer RJ, 2000, J CLIN ONCOL, V18, P1928, DOI 10.1200/JCO.2000.18.9.1928
   Oberg HH, 2006, SCAND J IMMUNOL, V64, P353, DOI 10.1111/j.1365-3083.2006.01825.x
   Onishi H, 2012, ANTICANCER RES, V32, P997
   Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Schwaab T, 2009, CLIN CANCER RES, V15, P4986, DOI 10.1158/1078-0432.CCR-08-3240
   Sehouli J, 2011, EPIGENETICS-US, V6, P236, DOI 10.4161/epi.6.2.13755
   Showe MK, 2009, CANCER RES, V69, P9202, DOI 10.1158/0008-5472.CAN-09-1378
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tatsugami K, 2010, J INTERF CYTOK RES, V30, P43, DOI 10.1089/jir.2009.0014
   Team RDC, 2010, R LANG ENV STAT COMP
   Twine N, 2003, CANCER RES, P1
   Wang Y, 2012, J CELL MOL MED, V16, P425, DOI 10.1111/j.1582-4934.2011.01437.x
   Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361
   Wolf AM, 2003, CLIN CANCER RES, V9, P606
   Wolf B, 2012, PLOS ONE
   Yao X, 2012, BLOOD, V119, P5688, DOI 10.1182/blood-2011-10-386482
   Yi HF, 2006, CELL MOL IMMUNOL, V3, P189
   Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547
   Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747
   Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586
NR 41
TC 11
Z9 13
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2012
VL 7
IS 10
AR e46600
DI 10.1371/journal.pone.0046600
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 030WJ
UT WOS:000310600500007
PM 23118856
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Baru, AM
   Untucht, C
   Ganesh, V
   Hesse, C
   Mayer, CT
   Sparwasser, T
AF Baru, Abdul Mannan
   Untucht, Christopher
   Ganesh, Venkateswaran
   Hesse, Christina
   Mayer, Christian T.
   Sparwasser, Tim
TI Optimal Isolation of Functional Foxp3(+) Induced Regulatory T Cells
   Using DEREG Mice
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXP3; SELECTIVE DEPLETION; TH2 RESPONSES;
   RETINOIC-ACID; TARGET GENES; IN-VIVO; INFLAMMATION; STIMULATION;
   ANTIBODIES; INFECTION
AB Foxp3 reporter mice including DEREG (DEpletion of REGulatory T cells) mice have greatly helped in exploring the biology of Foxp3(+) Tregs. DEREG mice express a DTR-eGFP fusion protein under the control of a bacterial artificial chromosome (BAC)-encoded Foxp3 promoter, allowing the viable isolation and inducible depletion of Foxp3(+) Tregs. Adaptive Tregs differentiated in vitro to express Foxp3 (iTregs) are gaining high interest as potential therapeutics for inflammatory conditions such as autoimmunity, allergy and transplant rejection. However, selective isolation of Foxp3(+) iTregs with a stable phenotype still remains to be a problem, especially in the human setting. While screening for culture conditions to generate stable CD4(+) Foxp3(+) iTregs from DEREG mice, with maximum suppressive activity, we observed an unexpected dichotomy of eGFP and Foxp3 expression which is not seen in ex vivo isolated cells from DEREG mice. Further characterization of eGFP(+) Foxp3(-) cells revealed relatively lower CD25 expression and a lack of suppressive activity in vitro. Similarly, eGFP(-) cells isolated from the same cultures were not suppressive despite of a broad CD25 expression reflecting mere T cell activation. In contrast, eGFP(+) Foxp3(+) iTregs exhibited potent suppressive activity comparable to that of natural eGFP(+) Foxp3(+) Tregs, emphasizing the importance of isolating Foxp3 expressing iTregs. Interestingly, the use of plate-bound anti-CD3 and anti-CD28 or Flt3L-driven BMDC resulted in considerable resolution of the observed dichotomy. In summary, we defined culture conditions for efficient generation of eGFP(+) Foxp3(+) iTregs by use of DEREG mice. Isolation of functional Foxp3(+) iTregs using DEREG mice can also be achieved under sub-optimal conditions based on the magnitude of surface CD25 expression, in synergy with transgene encoded eGFP. Besides, the reported phenomenon may be of general interest for exploring Foxp3 gene regulation, given that Foxp3 and eGFP expression are driven from distinct Foxp3 loci and because this dichotomy preferentially occurs only under defined in vitro conditions.
C1 [Baru, Abdul Mannan; Untucht, Christopher; Ganesh, Venkateswaran; Hesse, Christina; Mayer, Christian T.; Sparwasser, Tim] Ctr Expt & Clin Infect Res, Inst Infect Immunol, TWINCORE, Hannover, Germany.
RP Baru, AM (reprint author), Ctr Expt & Clin Infect Res, Inst Infect Immunol, TWINCORE, Hannover, Germany.
EM Tim.Sparwasser@twincore.de
FU Deutsche Forschungsgemeinschaft [SFB587 (Sonderforschungsbereich 587)];
   Research Training Group (German Research Foundation) [GRK 1441]; German
   National Academic Foundation; Research Training Group [GRK 1441];
   Braukmann-Wittenberg-Herz-Stiftung
FX This work was supported by the Deutsche Forschungsgemeinschaft SFB587
   (Sonderforschungsbereich 587). CH was supported by Research Training
   Group (German Research Foundation-GRK 1441) and CTM was supported by a
   stipend from the German National Academic Foundation. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.; We thank Christine Jaenke for
   technical assistance. This work was supported by the Deutsche
   Forschungsgemeinschaft SFB587 (Sonderforschungsbereich 587). CH was
   supported by Research Training Group (GRK 1441) and CTM was supported by
   a stipend from the German National Academic Foundation. We would further
   like to thank the Cell Sorting Core Facility of the Hannover Medical
   School supported in part by the Braukmann-Wittenberg-Herz-Stiftung and
   Deutsche Forschungsgemeinschaft. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Baru AM, 2010, EUR J IMMUNOL, V40, P2259, DOI 10.1002/eji.200939972
   Berod L, 2011, MICROB BIOTECHNOL, V5, P260
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Fyhrquist N, 2012, J INVEST DERMATOL, V132, P1672, DOI 10.1038/jid.2012.40
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Kim J, 2009, J IMMUNOL, V183, P7631, DOI 10.4049/jimmunol.0804308
   Klages K, 2010, CANCER RES, V70, P7788, DOI 10.1158/0008-5472.CAN-10-1736
   Koenecke C, 2009, EUR J IMMUNOL, V39, P3091, DOI 10.1002/eji.200939432
   Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852
   Lahl K, 2011, METHODS MOL BIOL, V707, P157, DOI 10.1007/978-1-61737-979-6_10
   Loebbermann J, 2012, MUCOSAL IMMUNOL, V5, P161, DOI 10.1038/mi.2011.62
   MANGER B, 1987, J IMMUNOL, V139, P2755
   Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478
   Mayer CT, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00183
   Mayer CT, 2012, BLOOD, V119, P1314, DOI 10.1182/blood-2011-11-392266
   Mayer CT, 2011, EUR J IMMUNOL, V41, P716, DOI 10.1002/eji.201040913
   Miyao T, 2012, IMMUNITY, V36, P262, DOI 10.1016/j.immuni.2011.12.012
   Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697
   Rausch S, 2009, EUR J IMMUNOL, V39, P3066, DOI 10.1002/eji.200939644
   Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139
   Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183
   VANLIER RAW, 1989, IMMUNOLOGY, V68, P45
   Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563
NR 26
TC 8
Z9 8
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2012
VL 7
IS 9
AR e44760
DI 10.1371/journal.pone.0044760
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 001MC
UT WOS:000308463800100
PM 22957107
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Jeker, LT
   Zhou, XY
   Gershberg, K
   de Kouchkovsky, D
   Morar, MM
   Stadthagen, G
   Lund, AH
   Bluestone, JA
AF Jeker, Lukas T.
   Zhou, Xuyu
   Gershberg, Kseniya
   de Kouchkovsky, Dimitri
   Morar, Malika M.
   Stadthagen, Gustavo
   Lund, Anders H.
   Bluestone, Jeffrey A.
TI MicroRNA 10a Marks Regulatory T Cells
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXP3; RETINOIC-ACID; REG-CELLS; IN-VIVO;
   DIFFERENTIATION; SPECIFICATION; GENERATION; RESPONSES; DICER; LEADS
AB MicroRNAs (miRNAs) are crucial for regulatory T cell (Treg) stability and function. We report that microRNA-10a (miR-10a) is expressed in Tregs but not in other T cells including individual thymocyte subsets. Expression profiling in inbred mouse strains demonstrated that non-obese diabetic (NOD) mice with a genetic susceptibility for autoimmune diabetes have lower Treg-specific miR-10a expression than C57BL/6J autoimmune resistant mice. Inhibition of miR-10a expression in vitro leads to reduced FoxP3 expression levels and miR-10a expression is lower in unstable "exFoxP3" T cells. Unstable in vitro TGF-beta-induced, iTregs do not express miR-10a unless cultured in the presence of retinoic acid (RA) which has been associated with increased stability of iTreg, suggesting that miR-10a might play a role in stabilizing Treg. However, genetic ablation of miR-10a neither affected the number and phenotype of natural Treg nor the capacity of conventional T cells to induce FoxP3 in response to TGF beta, RA, or a combination of the two. Thus, miR-10a is selectively expressed in Treg but inhibition by antagomiRs or genetic ablation resulted in discordant effects on FoxP3.
C1 [Jeker, Lukas T.; Zhou, Xuyu; Gershberg, Kseniya; de Kouchkovsky, Dimitri; Morar, Malika M.; Bluestone, Jeffrey A.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
   [Jeker, Lukas T.; Zhou, Xuyu; Gershberg, Kseniya; de Kouchkovsky, Dimitri; Morar, Malika M.; Bluestone, Jeffrey A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Stadthagen, Gustavo; Lund, Anders H.] Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark.
RP Jeker, LT (reprint author), Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
EM Jeff.bluestone@ucsf.edu
RI Lund, Anders H./F-4786-2014; Zhou, Xuyu/L-7422-2019
OI Lund, Anders H./0000-0002-7407-3398; Zhou, Xuyu/0000-0002-6626-0898;
   Jeker, Lukas/0000-0002-3359-8796; de Kouchkovsky,
   Dimitri/0000-0002-9609-3226
FU National Institutes of Health [P01 AI35297, U19 AI056388, P30 DK63720];
   Juvenile Diabetes Research Foundation; Swiss National Science Foundation
   (SNSF) [PBBSB-118644]; Swiss Foundation for Grants in Biology and
   Medicine (SFGBM)/SNSF [PASMP3-124274/1]; Roche Research Foundation;
   Novartis Foundation; ADA Mentor-Based Award; Lundbeck Foundation
   [R31-2007-1447]
FX This work was supported by National Institutes of Health Grants P01
   AI35297 and U19 AI056388 (to JAB), P30 DK63720 (for core support;
   http://www.nih.gov), and a Scholar Award from the Juvenile Diabetes
   Research Foundation (to JAB; http://www.jdrf.org/). LTJ was supported by
   the Swiss National Science Foundation (SNSF) (PBBSB-118644), and the
   Swiss Foundation for Grants in Biology and Medicine (SFGBM)/SNSF
   (PASMP3-124274/1; http://www.snf.ch), the Roche Research Foundation
   (http://www.research-foundation.org), and the Novartis Foundation
   (formerly Ciba-Geigy Jubilee Foundation,
   http://www.jubilaeumsstiftung.novartis.com). XZ was supported by an ADA
   Mentor-Based Award (http://www.diabetes.org). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alvarez-Saavedra E, 2010, CURR BIOL, V20, P367, DOI 10.1016/j.cub.2009.12.051
   Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719
   Chong MMW, 2008, J EXP MED, V205, P2449, DOI [10.1084/jem.20071219090508c, 10.1084/jem.20081219]
   Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Jeker LT, 2010, J CLIN IMMUNOL, V30, P347, DOI 10.1007/s10875-010-9392-7
   Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Leung AKL, 2007, CELL, V130, P581, DOI 10.1016/j.cell.2007.08.010
   Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027
   Liston A, 2008, J EXP MED, V205, P1993, DOI 10.1084/jem.20081062
   Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012
   Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010
   Moltzahn F, 2011, CANCER RES, V71, P550, DOI 10.1158/0008-5472.CAN-10-1229
   Park CY, 2012, CELL REPORTS, V1, P385, DOI 10.1016/j.celrep.2012.02.008
   Patrick DM, 2010, J CLIN INVEST, V120, P3912, DOI 10.1172/JCI43604
   Riley JL, 2009, IMMUNITY, V30, P656, DOI 10.1016/j.immuni.2009.04.006
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009
   Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065
   Zhou XH, 2010, J IMMUNOL, V185, P2675, DOI 10.4049/jimmunol.1000598
   Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707
   Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774
NR 28
TC 64
Z9 75
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2012
VL 7
IS 5
AR e36684
DI 10.1371/journal.pone.0036684
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959VG
UT WOS:000305343500023
PM 22629323
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Yurchenko, E
   Shio, MT
   Huang, TC
   Martins, MD
   Szyf, M
   Levings, MK
   Olivier, M
   Piccirillo, CA
AF Yurchenko, Ekaterina
   Shio, Marina T.
   Huang, Tony C.
   Martins, Maria Da Silva
   Szyf, Moshe
   Levings, Megan K.
   Olivier, Martin
   Piccirillo, Ciriaco A.
TI Inflammation-Driven Reprogramming of CD4(+)Foxp3(+) Regulatory T Cells
   into Pathogenic Th1/Th17 T Effectors Is Abrogated by mTOR Inhibition in
   vivo
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXP3; IMMUNOLOGICAL SELF-TOLERANCE; ROR-GAMMA-T;
   LEISHMANIA-MAJOR; TGF-BETA; CPG OLIGODEOXYNUCLEOTIDES; SUPPRESSIVE
   FUNCTION; T(H)17 LINEAGE; CUTTING EDGE; TH17 CELLS
AB While natural CD4(+)Foxp3(+) regulatory T (nT(REG)) cells have long been viewed as a stable and distinct lineage that is committed to suppressive functions in vivo, recent evidence supporting this notion remains highly controversial. We sought to determine whether Foxp3 expression and the nT(REG) cell phenotype are stable in vivo and modulated by the inflammatory microenvironment. Here, we show that Foxp3(+) nT(REG) cells from thymic or peripheral lymphoid organs reveal extensive functional plasticity in vivo. We show that nT(REG) cells readily lose Foxp3 expression, destabilizing their phenotype, in turn, enabling them to reprogram into Th1 and Th17 effector cells. nT(REG) cell reprogramming is a characteristic of the entire Foxp3(+) nT(REG) population and the stable Foxp3(NEG) T-REG cell phenotype is associated with a methylated foxp3 promoter. The extent of nT(REG) cell reprogramming is modulated by the presence of effector T cell-mediated signals, and occurs independently of variation in IL-2 production in vivo. Moreover, the gut microenvironment or parasitic infection favours the reprogramming of Foxp3(+) T-REG cells into effector T cells and promotes host immunity. IL-17 is predominantly produced by reprogrammed Foxp3(+) nT(REG) cells, and precedes Foxp3 down-regulation, a process accentuated in mesenteric sites. Lastly, mTOR inhibition with the immunosuppressive drug, rapamycin, stabilizes Foxp3 expression in T-REG cells and strongly inhibits IL-17 but not ROR gamma t expression in reprogrammed Foxp3(-) T-REG cells. Overall, inflammatory signals modulate mTOR signalling and influence the stability of the Foxp3(+) nT(REG) cell phenotype.
C1 [Yurchenko, Ekaterina; Shio, Marina T.; Martins, Maria Da Silva; Olivier, Martin; Piccirillo, Ciriaco A.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
   [Yurchenko, Ekaterina; Shio, Marina T.; Martins, Maria Da Silva; Olivier, Martin; Piccirillo, Ciriaco A.] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Huang, Tony C.; Szyf, Moshe; Olivier, Martin] McGill Univ, Dept Pharmacol, Montreal, PQ H3A 2T5, Canada.
   [Levings, Megan K.] Univ British Columbia, Dept Surg, Child & Family Res Inst, Vancouver, BC V6T 1W5, Canada.
   [Piccirillo, Ciriaco A.] McGill Univ, Res Inst, Ctr Hlth, FOCIS Ctr Excellence, Montreal, PQ, Canada.
RP Yurchenko, E (reprint author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
EM Ciro.piccirillo@mcgill.ca
OI Levings, Megan/0000-0002-0305-5790
FU Canadian Institutes for Health Research [MOP 67211, MOP 84037]
FX The authors acknowledge the financial support of the Canadian Institutes
   for Health Research (MOP 67211 and MOP 84037 to C. A. P.). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript
CR Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341
   Ayyoub M, 2009, P NATL ACAD SCI USA, V106, P8635, DOI 10.1073/pnas.0900621106
   Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338
   Bennett CL, 2001, NAT GENET, V27, P20
   Beriou G, 2009, BLOOD, V113, P4240, DOI 10.1182/blood-2008-10-183251
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Contreras I, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001148
   d'Hennezel E, 2009, NEW ENGL J MED, V361, P1710, DOI 10.1056/NEJMc0907093
   Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014
   Duarte JH, 2009, EUROPEAN J IMMUNOLOG, V9999
   Ehrchen JM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000871
   Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228
   Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543
   Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Horwitz DA, 2008, TRENDS IMMUNOL, V29, P429, DOI 10.1016/j.it.2008.06.005
   Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474
   Joshi PB, 2002, MOL BIOCHEM PARASIT, V120, P33, DOI 10.1016/S0166-6851(01)00432-7
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106
   Kopf H, 2007, INT IMMUNOPHARMACOL, V7, P1819, DOI 10.1016/j.intimp.2007.08.027
   MALEK TR, 2008, ANNU REV IMMUNOL, V26, P453, DOI DOI 10.1146/ANNUREV.IMMUNOL.26.021607.090357
   Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754
   MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q
   Murai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791
   Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137
   Piccirillo CA, 2008, CURR OPIN IMMUNOL, V20, P655, DOI 10.1016/j.coi.2008.09.006
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105
   Schaefer BC, 2001, CELL IMMUNOL, V214, P110, DOI 10.1006/cimm.2001.1895
   Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982
   Sgouroudis E, 2008, J IMMUNOL, V181, P6283, DOI 10.4049/jimmunol.181.9.6283
   Strauss L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005994
   Tang Q, 2008, IMMUNITY, V28, P687, DOI 10.1016/j.immuni.2008.03.016
   Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152
   Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102
   Weigmann B, 2007, NAT PROTOC, V2, P2307, DOI 10.1038/nprot.2007.315
   Wu WH, 2006, EUR J IMMUNOL, V36, P3238, DOI 10.1002/eji.200636472
   Wu WH, 2009, CAN J MICROBIOL, V55, P705, DOI [10.1139/W09-017, 10.1139/w09-017]
   Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725
   Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007
   Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878
   Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774
NR 51
TC 73
Z9 77
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2012
VL 7
IS 4
AR e35572
DI 10.1371/journal.pone.0035572
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959VE
UT WOS:000305343200038
PM 22545118
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Tian, Y
   Jia, ZC
   Wang, J
   Huang, ZM
   Tang, J
   Zheng, YH
   Tang, Y
   Wang, QH
   Tian, ZQ
   Yang, D
   Zhang, Y
   Fu, XL
   Song, JX
   Liu, SL
   van Velkinburgh, JC
   Wu, YZ
   Ni, B
AF Tian, Yi
   Jia, Zhengcai
   Wang, Jun
   Huang, Zemin
   Tang, Jun
   Zheng, Yanhua
   Tang, Yan
   Wang, Qinghong
   Tian, Zhiqiang
   Yang, Di
   Zhang, Yi
   Fu, Xiaolan
   Song, Jianxun
   Liu, Shunli
   van Velkinburgh, Jennifer C.
   Wu, Yuzhang
   Ni, Bing
TI Global Mapping of H3K4me1 and H3K4me3 Reveals the Chromatin State-Based
   Cell Type-Specific Gene Regulation in Human Treg Cells
SO PLOS ONE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; T-CELLS; GENOME-WIDE; HISTONE MODIFICATIONS; FOXP3
   EXPRESSION; DNA METHYLATION; SACCHAROMYCES-CEREVISIAE; ACETYLATION;
   PROMOTERS; LINEAGE
AB Regulatory T cells (Treg) contribute to the crucial immunological processes of self-tolerance and immune homeostasis. Genomic mechanisms that regulate cell fate decisions leading to Treg or conventional T cells (Tconv) lineages and those underlying Treg function remain to be fully elucidated, especially at the histone modification level. We generated high-resolution genome-wide distribution maps of monomethylated histone H3 lysine 4 (H3K4me1) and trimethylated H3K4 (H3K4me3) in human CD4(+)CD25(+)FOXP3(+) Tregs and CD4(+)CD25(+)FOXP3(-) activated (a) Tconv cells by DNA sequencing-by-synthesis. 2115 H3K4me3 regions corresponded to proximal promoters; in Tregs, the genes associated with these regions included the master regulator FOXP3 and the chemokine (C-C motif) receptor 7 (CCR7). 41024 Treg-specific H3K4me1 regions were identified. The majority of the H3K4me1 regions differing between Treg and aTconv cells were located at promoter-distal sites, and in vitro reporter gene assays were used to evaluate and identify novel enhancer activity. We provide for the first time a comprehensive genome-wide dataset of lineage-specific H3K4me1 and H3K4me3 patterns in Treg and aTconv cells, which may control cell type-specific gene regulation. This basic principle is likely not restricted to the two closely-related T cell populations, but may apply generally to somatic cell lineages in adult organisms.
C1 [Tian, Yi; Jia, Zhengcai; Huang, Zemin; Tang, Jun; Zheng, Yanhua; Tang, Yan; Wang, Qinghong; Tian, Zhiqiang; Yang, Di; Zhang, Yi; Fu, Xiaolan; Liu, Shunli; Wu, Yuzhang; Ni, Bing] Third Mil Med Univ, PLA, Inst Immunol, Chongqing, Peoples R China.
   [Wang, Jun] Beijing Genom Inst Branch Shenzhen, Shenzhen, Peoples R China.
   [Song, Jianxun] Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA USA.
   [van Velkinburgh, Jennifer C.] Initiat Collaboratory BioMed Res, Santa Fe, NM USA.
RP Tian, Y (reprint author), Third Mil Med Univ, PLA, Inst Immunol, Chongqing, Peoples R China.
EM wuyuzhang@yahoo.com; nibingxi@yahoo.com
RI Wang, Jun/C-8434-2016; wang, qinghong/M-7969-2017
OI Wang, Jun/0000-0002-8540-8931; van Velkinburgh,
   Jennifer/0000-0002-4592-2397; Wang, Jun/0000-0002-2113-5874; Ni,
   Bing/0000-0002-4297-5346
FU Major State Basic Research Development Program of China (973 Program)
   [2007CB512805, 2007CB512401]; National Natural Science Foundation of
   China [30771950, 31070798]; Chongqing Science and Technology Committee
   [2008BB5033]
FX This work was supported by grants from the Major State Basic Research
   Development Program of China (973 Program) (Nos. 2007CB512805 and
   2007CB512401), http://www.most.gov.cn/index.htm, the General Program of
   National Natural Science Foundation of China (No. 30771950, and
   31070798), http://www.nsfc.gov.cn/ and the Chongqing Science and
   Technology Committee (2008BB5033), http://www.ctin.ac.cn/. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Antov A, 2003, J IMMUNOL, V171, P3435, DOI 10.4049/jimmunol.171.7.3435
   Araki Y, 2008, J IMMUNOL, V180, P8102, DOI 10.4049/jimmunol.180.12.8102
   Arya M, 2005, EXPERT REV MOL DIAGN, V5, P209, DOI 10.1586/14737159.5.2.209
   Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Chong MMW, 2008, J EXP MED, V205, P2449, DOI [10.1084/jem.20071219090508c, 10.1084/jem.20081219]
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, J EXP MED, V202, P901, DOI 10.1084/jem.20050784
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409
   Hon G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000566
   HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X
   Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400
   Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025
   Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336
   Liston A, 2008, J EXP MED, V205, P1993, DOI 10.1084/jem.20081062
   Liston A, 2008, P NATL ACAD SCI USA, V105, P11903, DOI 10.1073/pnas.0801506105
   Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Millar CB, 2006, NAT REV MOL CELL BIO, V7, P657, DOI 10.1038/nrm1986
   Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506
   Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216
   Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002
   ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455
   Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103
   Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505
   Schmidl C, 2009, GENOME RES, V19, P1165, DOI 10.1101/gr.091470.109
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343
   WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009
   Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1081/jem.20030422
   Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178
   Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707
   Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747
NR 54
TC 22
Z9 23
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 23
PY 2011
VL 6
IS 11
AR e27770
DI 10.1371/journal.pone.0027770
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 863KL
UT WOS:000298162000041
PM 22132139
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Lu, L
   Ma, JL
   Li, ZY
   Lan, Q
   Chen, MG
   Liu, Y
   Xia, ZX
   Wang, J
   Han, YP
   Shi, W
   Quesniaux, V
   Ryffel, B
   Brand, D
   Li, B
   Liu, ZM
   Zheng, SG
AF Lu, Ling
   Ma, Jilin
   Li, Zhiyuan
   Lan, Qin
   Chen, Maogen
   Liu, Ya
   Xia, Zanxian
   Wang, Julie
   Han, Yuanping
   Shi, Wei
   Quesniaux, Valerie
   Ryffel, Bernhard
   Brand, David
   Li, Bin
   Liu, Zhongmin
   Zheng, Song Guo
TI All-Trans Retinoic Acid Promotes TGF-beta-Induced Tregs via Histone
   Modification but Not DNA Demethylation on Foxp3 Gene Locus
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; HOST-DISEASE; TH17 CELLS; EXPRESSION; SMAD3;
   BINDING; DIFFERENTIATION; ACTIVATION; RECEPTORS; INDUCTION
AB Background: It has been documented all-trans retinoic acid (atRA) promotes the development of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells (iTreg) that play a vital role in the prevention of autoimmune responses, however, molecular mechanisms involved remain elusive. Our objective, therefore, was to determine how atRA promotes the differentiation of iTregs.
   Methodology/Principal Findings: Addition of atRA to naive CD4(+)CD25(-) cells stimulated with anti-CD3/CD28 antibodies in the presence of TGF-beta not only increased Foxp3(+) iTreg differentiation, but maintained Foxp3 expression through apoptosis inhibition. atRA/TGF-beta-treated CD4(+) cells developed complete anergy and displayed increased suppressive activity. Infusion of atRA/TGF-beta-treated CD4(+) cells resulted in the greater effects on suppressing symptoms and protecting the survival of chronic GVHD mice with typical lupus-like syndromes than did CD4(+) cells treated with TGF-beta alone. atRA did not significantly affect the phosphorylation levels of Smad2/3 and still promoted iTreg differentiation in CD4(+) cells isolated from Smad3 KO and Smad2 conditional KO mice. Conversely, atRA markedly increased ERK1/2 activation, and blockade of ERK1/2 signaling completely abolished the enhanced effects of atRA on Foxp3 expression. Moreover, atRA significantly increased histone methylation and acetylation within the promoter and conserved non-coding DNA sequence (CNS) elements at the Foxp3 gene locus and the recruitment of phosphor-RNA polymerase II, while DNA methylation in the CNS3 was not significantly altered.
   Conclusions/Significance: We have identified the cellular and molecular mechanism(s) by which atRA promotes the development and maintenance of iTregs. These results will help to enhance the quantity and quality of development of iTregs and may provide novel insights into clinical cell therapy for patients with autoimmune diseases and those needing organ transplantation.
C1 [Lu, Ling; Lan, Qin; Chen, Maogen; Liu, Ya; Xia, Zanxian; Wang, Julie; Zheng, Song Guo] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Saban Res Inst,Dept Med,Div Rheumat, Los Angeles, CA 90033 USA.
   [Han, Yuanping] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Saban Res Inst,Dept Surg, Los Angeles, CA 90033 USA.
   [Shi, Wei] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Saban Res Inst,Dev Biol & Regenerat Med Program, Los Angeles, CA 90033 USA.
   [Lu, Ling] Key Lab Living Donor Liver Transplantat, Nanjing, Peoples R China.
   [Ma, Jilin] Zhejiang Tradit Chinese Med & Western Med Hosp, Div Rheumatol Immunol & Nephrol, Hangzhou, Zhejiang, Peoples R China.
   [Lan, Qin; Liu, Zhongmin] Tongji Univ, Immune Tolerance Ctr, Shanghai E Hosp, Shanghai 200092, Peoples R China.
   [Quesniaux, Valerie; Ryffel, Bernhard; Zheng, Song Guo] Univ & Ctr Natl Rech Sci, UMR6218, Orleans, France.
   [Brand, David] Vet Affairs Med Ctr, Res Serv, Memphis, TN USA.
   [Li, Zhiyuan; Li, Bin] Chinese Acad Sci, Unit Mol Immunol, Inst Pasteur Shanghai, Shanghai, Peoples R China.
RP Lu, L (reprint author), Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Saban Res Inst,Dept Med,Div Rheumat, Los Angeles, CA 90033 USA.
EM zhongmin_liu@sina.com
OI Brand, David/0000-0002-9260-7963
FU National Institutes of Health [R01 AR059103, R01 AR051558, R01
   HL068597]; ACR; Arthritis Foundation; National Natural Science
   Foundation of China [30728007, 30772150, 81001307, 81100270]; Zhejiang
   Province National Natural Science Foundation of China [Y2090918]
FX This work was supported by National Institutes of Health grants R01
   AR059103, R01 AR051558, and R01 HL068597; ACR Within Our Reach; the
   Arthritis Foundation; an Outstanding Youth Scientist Award from the
   National Natural Science Foundation of China (30728007); the National
   Natural Science Foundation of China (30772150, 81001307, and 81100270);
   and Zhejiang Province National Natural Science Foundation of China
   (Y2090918). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alique M, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-1
   Chapman RD, 2007, SCIENCE, V318, P1780, DOI 10.1126/science.1145977
   Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61
   Hill JA, 2008, IMMUNITY, V29, P758, DOI 10.1016/j.immuni.2008.09.018
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483
   Kang SG, 2007, J IMMUNOL, V179, P3724, DOI 10.4049/jimmunol.179.6.3724
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   Komi Y, 2010, LAB INVEST, V90, P52, DOI 10.1038/labinvest.2009.110
   Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104
   Li B, 2009, J IMMUNOL, V182, P7625, DOI 10.4049/jimmunol.0804192
   Lu L, 2010, J IMMUNOL, V184, P4295, DOI 10.4049/jimmunol.0903418
   Lu L, 2010, EUR J IMMUNOL, V40, P142, DOI 10.1002/eji.200939618
   Maynard CL, 2009, J EXP MED, V206, P343, DOI 10.1084/jem.20080950
   Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697
   Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121, DOI 10.1016/S0968-0004(00)01551-6
   Nolting J, 2009, J EXP MED, V206, P2131, DOI 10.1084/jem.20090639
   NUGENT P, 1995, EXP CELL RES, V220, P495, DOI 10.1006/excr.1995.1341
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6
   RACKE MK, 1995, J IMMUNOL, V154, P450
   Reifen R, 2002, J NUTR, V132, P2743
   ROLINK AG, 1982, J EXP MED, V155, P1501, DOI 10.1084/jem.155.5.1501
   Sakoe Y, 2010, BLOOD, V115, P3787, DOI 10.1182/blood-2009-05-222976
   Samanta A, 2008, P NATL ACAD SCI USA, V105, P14023, DOI 10.1073/pnas.0806726105
   Schambach F, 2007, EUR J IMMUNOL, V37, P2396, DOI 10.1002/eji.200737621
   Takimoto T, 2010, J IMMUNOL, V185, P842, DOI 10.4049/jimmunol.0904100
   Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549
   Ueki S, 2008, J IMMUNOL, V181, P7689, DOI 10.4049/jimmunol.181.11.7689
   van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118
   Van YH, 2009, DIABETES, V58, P146, DOI 10.2337/db08-1154
   Verrier L, 2011, BIOL CELL, V103, P381, DOI 10.1042/BC20110028
   Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009
   Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9
   Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277
   Xu LL, 2010, IMMUNITY, V33, P313, DOI 10.1016/j.immuni.2010.09.001
   Zhang H, 2004, INT J ONCOL, V25, P1241
   Zhang Q, 2007, NAT MED, V13, P1341, DOI 10.1038/nm1659
   Zheng SG, 2004, J IMMUNOL, V172, P1531, DOI 10.4049/jimmunol.172.3.1531
   Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018
   Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750
   Zhou XH, 2010, J IMMUNOL, V185, P2675, DOI 10.4049/jimmunol.1000598
   Zhou XH, 2010, J MOL CELL BIOL, V2, P164, DOI 10.1093/jmcb/mjq007
   Zunino SJ, 2007, J NUTR, V137, P1216
NR 45
TC 46
Z9 53
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2011
VL 6
IS 9
AR e24590
DI 10.1371/journal.pone.0024590
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 825ZV
UT WOS:000295321800035
PM 21931768
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Golovina, TN
   Mikheeva, T
   Brusko, TM
   Blazar, BR
   Bluestone, JA
   Riley, JL
AF Golovina, Tatiana N.
   Mikheeva, Tatiana
   Brusko, Todd M.
   Blazar, Bruce R.
   Bluestone, Jeffrey A.
   Riley, James L.
TI Retinoic Acid and Rapamycin Differentially Affect and Synergistically
   Promote the Ex Vivo Expansion of Natural Human T Regulatory Cells
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-BETA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; DE-NOVO
   GENERATION; TGF-BETA; TRANSPLANTATION TOLERANCE; INFECTIOUS TOLERANCE;
   PERIPHERAL-BLOOD; FOXP3 EXPRESSION; CUTTING EDGE; IN-VIVO
AB Natural T regulatory cells (Tregs) are challenging to expand ex vivo, and this has severely hindered in vivo evaluation of their therapeutic potential. All trans retinoic acid (ATRA) plays an important role in mediating immune homeostasis in vivo, and we investigated whether ATRA could be used to promote the ex vivo expansion of Tregs purified from adult human peripheral blood. We found that ATRA helped maintain FOXP3 expression during the expansion process, but this effect was transient and serum-dependent. Furthermore, natural Tregs treated with rapamycin, but not with ATRA, suppressed cytokine production in co-cultured effector T cells. This suppressive activity correlated with the ability of expanded Tregs to induce FOXP3 expression in non-Treg cell populations. Examination of CD45RA+ and CD45RA- Treg subsets revealed that ATRA failed to maintain suppressive activity in either population, but interestingly, Tregs expanded in the presence of both rapamycin and ATRA displayed more suppressive activity and had a more favorable epigenetic status of the FOXP3 gene than Tregs expanded in the presence of rapamycin only. We conclude that while the use of ATRA as a single agent to expand Tregs for human therapy is not warranted, its use in combination with rapamycin may have benefit.
C1 [Golovina, Tatiana N.; Mikheeva, Tatiana; Riley, James L.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Golovina, Tatiana N.; Mikheeva, Tatiana; Riley, James L.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Brusko, Todd M.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
   [Blazar, Bruce R.; Bluestone, Jeffrey A.] Univ Minnesota, Ctr Canc, Minneapolis, MN USA.
   [Blazar, Bruce R.; Bluestone, Jeffrey A.] Univ Minnesota, Dept Pediat, Div Bone Marrow Transplant, Minneapolis, MN 55455 USA.
RP Golovina, TN (reprint author), Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
EM rileyj@exchange.upenn.edu
OI Riley, James/0000-0002-1057-576X
FU Juvenile Diabetes Research Foundation Collaborative Centers for Cell
   Therapy; JDRF Center on Cord Blood Therapies for Type 1 Diabetes,
   Leukemia and Lymphoma Translational Research [R6029-07];  [P01 CA067493]
FX This work was supported in part by Juvenile Diabetes Research Foundation
   Collaborative Centers for Cell Therapy and the JDRF Center on Cord Blood
   Therapies for Type 1 Diabetes, Leukemia and Lymphoma Translational
   Research (grant R6029-07) and P01 CA067493. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Allan SE, 2008, IMMUNOL REV, V223, P391, DOI 10.1111/j.1600-065X.2008.00634.x
   Andersson J, 2008, J EXP MED, V205, P1975, DOI 10.1084/jem.20080308
   Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Basu S, 2008, J IMMUNOL, V180, P5794, DOI 10.4049/jimmunol.180.9.5794
   Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932
   Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338
   Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719
   Berger C, 2008, J CLIN INVEST, V118, P294, DOI 10.1172/JCI32103
   Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032
   Bonewald LF, 1997, ENDOCRINOLOGY, V138, P657, DOI 10.1210/en.138.2.657
   Chai JG, 2005, TRANSPLANTATION, V79, P1310, DOI 10.1097/01.TP.0000159147.56408.9C
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002
   Elias KM, 2008, BLOOD, V111, P1013, DOI 10.1182/blood-2007-06-096438
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fox CJ, 2005, J EXP MED, V201, P259, DOI 10.1084/jem.20042020
   Golovina TN, 2008, J IMMUNOL, V181, P2855, DOI 10.4049/jimmunol.181.4.2855
   Hill JA, 2008, IMMUNITY, V29, P758, DOI 10.1016/j.immuni.2008.09.018
   Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399
   Hoffmann P, 2006, BLOOD, V108, p903A
   Huter EN, 2008, J IMMUNOL, V181, P8209, DOI 10.4049/jimmunol.181.12.8209
   Ito T, 2008, IMMUNITY, V28, P870, DOI 10.1016/j.immuni.2008.03.018
   Kang SG, 2007, J IMMUNOL, V179, P3724, DOI 10.4049/jimmunol.179.6.3724
   Kim CH, 2008, CLIN DEV IMMUNOL, P1, DOI 10.1155/2008/416910
   Koenecke C, 2009, EUR J IMMUNOL, V39, P3091, DOI 10.1002/eji.200939432
   Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106
   Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584
   Lehmann J, 2002, P NATL ACAD SCI USA, V99, P13031, DOI 10.1073/pnas.192162899
   Maynard CL, 2009, J EXP MED, V206, P343, DOI 10.1084/jem.20080950
   Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019
   Moore C, 2009, TRANSPL P, V41, P2670, DOI 10.1016/j.transproceed.2009.06.130
   Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697
   Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629
   QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901
   RACKE MK, 1995, J IMMUNOL, V154, P450
   Reifen R, 2002, J NUTR, V132, P2743
   Riley JL, 2009, IMMUNITY, V30, P656, DOI 10.1016/j.immuni.2009.04.006
   Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9
   Schambach F, 2007, EUR J IMMUNOL, V37, P2396, DOI 10.1002/eji.200737621
   Selvaraj RK, 2008, J IMMUNOL, V180, P2830, DOI 10.4049/jimmunol.180.5.2830
   Suhoski MM, 2007, MOL THER, V15, P981, DOI 10.1038/mt.sj.6300134
   Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602
   Tarbell KV, 2007, J EXP MED, V204, P191, DOI 10.1084/jem.20061631
   Taylor P, 2004, BLOOD, V104, p16A
   Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656
   Varela-Rohena A, 2008, NAT MED, V14, P1390, DOI 10.1038/nm.1779
   Wang J, 2009, J IMMUNOL, V183, P4119, DOI 10.4049/jimmunol.0901065
   Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361
   Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277
   Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007
   Zheng SG, 2004, J IMMUNOL, V172, P5213, DOI 10.4049/jimmunol.172.9.5213
   Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774
   Ziegler SF, 2009, MICROBES INFECT, V11, P594, DOI 10.1016/j.micinf.2009.04.002
   Zunino SJ, 2007, J NUTR, V137, P1216
NR 55
TC 84
Z9 86
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 6
PY 2011
VL 6
IS 1
AR e15868
DI 10.1371/journal.pone.0015868
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 710KZ
UT WOS:000286511900018
PM 21253593
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Liu, J
   Lluis, A
   Illi, S
   Layland, L
   Olek, S
   von Mutius, E
   Schaub, B
AF Liu, Jing
   Lluis, Anna
   Illi, Sabina
   Layland, Laura
   Olek, Sven
   von Mutius, Erika
   Schaub, Bianca
TI T Regulatory Cells in Cord Blood-FOXP3 Demethylation as Reliable
   Quantitative Marker
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXP3; DNA METHYLATION ANALYSIS;
   FUNCTIONAL-CHARACTERIZATION; PERIPHERAL-BLOOD; EFFECTOR-CELLS;
   EXPRESSION; IMPAIRMENT; CHILDREN; INDUCTION; ALLERGY
AB Background: Regulatory T-cells (Tregs), characterized as CD4+CD25(hi) T-cells expressing FOXP3, play a crucial role in controlling healthy immune development during early immune maturation. Recently, FOXP3 demethylation was suggested to be a novel marker for natural Tregs in adults. In cord blood, the role and function of Tregs and its demethylation is poorly understood. We assessed FOXP3 demethylation in cord blood in relation to previously used Treg markers such as CD4(+)CD25(hi), FOXP3 mRNA, protein expression, and suppressive Treg function.
   Methodology: Cord blood mononuclear cells (CBMC) were isolated from 70 healthy neonates, stimulated for 3 days with the microbial stimulus lipid A (LpA), and allergen Dermatophagoides pteronyssinus (Derp1). Tregs (CD4+CD25(hi), intracellular, mRNA FOXP3 expression, isolated cells), DNA methylation of the FOXP3-locus and suppressive Treg function were assessed.
   Principal Findings: Demethylation of FOXP3 in whole blood was specific for isolated CD4+CD25(hi) Tregs. Demethylation of FOXP3 was positively correlated with unstimulated and LpA-stimulated FOXP3 mRNA-expression (p <= 0.05), and CD4(+)CD25(hi) T-cells (p <= 0.03). Importantly, increased FOXP3 demethylation correlated with more efficient suppressive capacity of Tregs (r = 0.72, p = 0.005). Furthermore, FOXP3 demethylation was positively correlated with Th2 cytokines (IL-5, IL-13) following LpA-stimulation (p = 0.006/0.04), with Th2 and IL-17 following Derp1+LpA-stimulations (p <= 0.009), but not Th1 cytokines (IFN-gamma).
   Conclusions: FOXP3 demethylation reliable quantifies Tregs in cord blood. FOXP3 demethylation corresponds well with the suppressive potential of Tregs. The resulting strict correlation with functionally suppressive Tregs and the relative ease of measurement render it into a valuable novel marker for large field studies assessing Tregs as qualitative marker indicative of functional activity.
C1 [Liu, Jing; Lluis, Anna; Illi, Sabina; von Mutius, Erika; Schaub, Bianca] Univ Munich, Univ Childrens Hosp Munich, Dept Pulm & Allergy, Munich, Germany.
   [Liu, Jing] Ji Lin Univ, Hosp 2, Dept Resp Med, Changchun, Peoples R China.
   [Layland, Laura] Tech Univ Munich, Inst Med Microbiol, Munich, Germany.
   [Olek, Sven] Epiontis GmbH, Berlin, Germany.
RP Liu, J (reprint author), Univ Munich, Univ Childrens Hosp Munich, Dept Pulm & Allergy, Munich, Germany.
EM Bianca.Schaub@med.uni-muenchen.de
RI Schaub, Bianca/B-9935-2019
OI von Mutius, Erika/0000-0002-8893-4515
FU Bayerische Forschungsstiftung; GALTRAIN; Munich University
FX Bayerische Forschungsstiftung, GALTRAIN, Munich University Grant (all
   BS). These funders had no role in study design, data collection and
   analysis, decision to publish or preparation of the manuscript.
   Additional funding was received through Epiontis (SO). SO is employed by
   Epiontis GmbH, and has supervised performance of experiments, and
   contributed analysis tools for these experiments.
CR Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Baecher-Allan C, 2004, SEMIN IMMUNOL, V16, P89, DOI 10.1016/j.smim.2003.12.005
   Baecher-Allan C, 2002, J IMMUNOL, V169, P6210, DOI 10.4049/jimmunol.169.11.6210
   Baron U, 2006, EPIGENETICS-US, V1, P55, DOI 10.4161/epi.1.1.2643
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774
   Cao D, 2003, EUR J IMMUNOL, V33, P215, DOI 10.1002/immu.200390024
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023
   Jartti T, 2007, J ALLERGY CLIN IMMUN, V120, P177, DOI 10.1016/j.jaci.2007.03.008
   Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285
   Kleinewietfeld M, 2009, BLOOD, V113, P827, DOI 10.1182/blood-2008-04-150524
   Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Pace L, 2006, J IMMUNOL, V176, P3900, DOI 10.4049/jimmunol.176.7.3900
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Prescott SL, 2008, ALLERGY, V63, P1481, DOI 10.1111/j.1398-9995.2008.01778.x
   Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6
   Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x
   Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010
   Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056
   Skapenko A, 2005, J IMMUNOL, V175, P6107, DOI 10.4049/jimmunol.175.9.6107
   SMITH M, 2008, J ALLERGY CLIN IMMUN, V121, P1466
   Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025
   Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x
   Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361
   Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697
   Zhang FP, 2008, NAT IMMUNOL, V9, P1297, DOI 10.1038/ni.1663
   Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455
   Ziegler SF, 2007, EUR J IMMUNOL, V37, P21, DOI 10.1002/eji.200636929
NR 37
TC 36
Z9 36
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 12
PY 2010
VL 5
IS 10
AR e13267
DI 10.1371/journal.pone.0013267
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 662KX
UT WOS:000282807300010
PM 20967272
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Brusko, TM
   Koya, RC
   Zhu, S
   Lee, MR
   Putnam, AL
   McClymont, SA
   Nishimura, MI
   Han, SH
   Chang, LJ
   Atkinson, MA
   Ribas, A
   Bluestone, JA
AF Brusko, Todd M.
   Koya, Richard C.
   Zhu, Shirley
   Lee, Michael R.
   Putnam, Amy L.
   McClymont, Stephanie A.
   Nishimura, Michael I.
   Han, Shuhong
   Chang, Lung-Ji
   Atkinson, Mark A.
   Ribas, Antoni
   Bluestone, Jeffrey A.
TI Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor
   Gene Transfer
SO PLOS ONE
LA English
DT Article
ID ADOPTIVE TRANSFER; AUTOIMMUNE-DISEASES; MELANOMA ANTIGEN; FOXP3
   EXPRESSION; CUTTING EDGE; EX-VIVO; EXPANSION; THERAPY; TOLERANCE;
   SUPPRESSION
AB Background: Therapies directed at augmenting regulatory T cell (Treg) activities in vivo as a systemic treatment for autoimmune disorders and transplantation may be associated with significant off-target effects, including a generalized immunosuppression that may compromise beneficial immune responses to infections and cancer cells. Adoptive cellular therapies using purified expanded Tregs represents an attractive alternative to systemic treatments, with results from animal studies noting increased therapeutic potency of antigen-specific Tregs over polyclonal populations. However, current methodologies are limited in terms of the capacity to isolate and expand a sufficient quantity of endogenous antigen-specific Tregs for therapeutic intervention. Moreover, FOXP3+ Tregs fall largely within the CD4+ T cell subset and are thus routinely MHC class II-specific, whereas class I-specific Tregs may function optimally in vivo by facilitating direct tissue recognition.
   Methodology/Principal Findings: To overcome these limitations, we have developed a novel means for generating large numbers of antigen-specific Tregs involving lentiviral T cell receptor (TCR) gene transfer into in vitro expanded polyclonal natural Treg populations. Tregs redirected with a high-avidity class I-specific TCR were capable of recognizing the melanoma antigen tyrosinase in the context of HLA-A*0201 and could be further enriched during the expansion process by antigen-specific reactivation with peptide loaded artificial antigen presenting cells. These in vitro expanded Tregs continued to express FOXP3 and functional TCRs, and maintained the capacity to suppress conventional T cell responses directed against tyrosinase, as well as bystander T cell responses. Using this methodology in a model tumor system, murine Tregs designed to express the tyrosinase TCR effectively blocked antigen-specific effector T cell (Teff) activity as determined by tumor cell growth and luciferase reporter-based imaging.
   Conclusions/Significance: These results support the feasibility of class I-restricted TCR transfer as a promising strategy to redirect the functional properties of Tregs and provide for a more efficacious adoptive cell therapy.
C1 [Brusko, Todd M.; Zhu, Shirley; Lee, Michael R.; Putnam, Amy L.; McClymont, Stephanie A.; Bluestone, Jeffrey A.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
   [Koya, Richard C.; Ribas, Antoni] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA.
   [Nishimura, Michael I.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
   [Han, Shuhong; Chang, Lung-Ji] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA.
   [Atkinson, Mark A.] Univ Florida, Coll Med, Dept Pathol & Lab Med, Gainesville, FL 32610 USA.
RP Brusko, TM (reprint author), Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
EM Jeff.Bluestone@ucsf.edu
FU NIH Autoimmunity Center of Excellence; Juvenile Diabetes Research
   Foundation Center; Dee and William Brehm Foundation for Diabetes
   Research; JDRF
FX This work was supported by, in part, by the NIH Autoimmunity Center of
   Excellence Grant as well as a Juvenile Diabetes Research Foundation
   Center Grant (Collaborative Center for Cell Therapy), and The Dee and
   William Brehm Foundation for Diabetes Research. T. B. is supported by a
   JDRF advanced post-doctoral fellowship grant. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abad JD, 2008, J IMMUNOTHER, V31, P1, DOI 10.1097/CJI.0b013e31815c193f
   Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341
   Alyanakian MA, 2003, P NATL ACAD SCI USA, V100, P15806, DOI 10.1073/pnas.2636971100
   Battaglia M, 2006, SEMIN IMMUNOL, V18, P120, DOI 10.1016/j.smim.2006.01.007
   BLUESTONE JA, 2004, PROCNATLACADSCIUSA
   Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527
   Brehm MA, 2010, CLIN IMMUNOL, V135, P84, DOI 10.1016/j.clim.2009.12.008
   Brusko TM, 2005, J IMMUNOL, V174, P5181, DOI 10.4049/jimmunol.174.9.5181
   Brusko Todd M, 2007, Immunol Invest, V36, P607, DOI 10.1080/08820130701790368
   Brusko TM, 2008, IMMUNOL REV, V223, P371, DOI 10.1111/j.1600-065X.2008.00637.x
   Brusko TM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007980
   Chatenoud L, 2001, IMMUNOL REV, V182, P149, DOI 10.1034/j.1600-065X.2001.1820112.x
   Chatenoud L, 2007, NAT REV IMMUNOL, V7, P622, DOI 10.1038/nri2134
   Cohen CJ, 2007, CANCER RES, V67, P3898, DOI 10.1158/0008-5472.CAN-06-3986
   DEAGLIO S, 2007, J EXP MED
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Govers C, 2010, TRENDS MOL MED, V16, P77, DOI 10.1016/j.molmed.2009.12.004
   Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010
   Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409
   Hoffmann P, 2009, EUR J IMMUNOL, V39, P1088, DOI 10.1002/eji.200838904
   Hombach AA, 2009, GENE THER, V16, P1088, DOI 10.1038/gt.2009.75
   Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474
   Kohm AP, 2002, J IMMUNOL, V169, P4712, DOI 10.4049/jimmunol.169.9.4712
   Levine BL, 2002, NAT MED, V8, P47, DOI 10.1038/nm0102-47
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Masteller EL, 2005, J IMMUNOL, V175, P3053, DOI 10.4049/jimmunol.175.5.3053
   Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143
   MITCHISON NA, 1955, J EXP MED, V102, P157, DOI 10.1084/jem.102.2.157
   Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939
   Nishimura MI, 1999, CANCER RES, V59, P6230
   Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077
   Paulos CM, 2008, IMMUNOL RES, V42, P182, DOI 10.1007/s12026-008-8070-9
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Porter DL, 2005, BONE MARROW TRANSPL, V35, P935, DOI 10.1038/sj.bmt.1704953
   Putnam AL, 2009, DIABETES, V58, P652, DOI 10.2337/db08-1168
   QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901
   Ribas A, 1997, CANCER RES, V57, P2865
   Riley JL, 2009, IMMUNITY, V30, P656, DOI 10.1016/j.immuni.2009.04.006
   Roszkowski JJ, 2005, CANCER RES, V65, P1570, DOI 10.1158/0008-5472.CAN-04-2076
   Roszkowski JJ, 2003, J IMMUNOL, V170, P2582, DOI 10.4049/jimmunol.170.5.2582
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Scalapino KJ, 2006, J IMMUNOL, V177, P1451, DOI 10.4049/jimmunol.177.3.1451
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   Setiady YY, 2006, BLOOD, V107, P1056, DOI 10.1182/blood-2005-08-3088
   St Clair EW, 2007, ANNU REV MED, V58, P329, DOI 10.1146/annurev.med.58.061705.145449
   Szymczak AL, 2005, EXPERT OPIN BIOL TH, V5, P627, DOI 10.1517/14712598.5.5.627
   Tahara H, 2003, J IMMUNOL, V171, P2154, DOI 10.4049/jimmunol.171.4.2154
   Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572
   Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139
   Thomas S, 2007, EXPERT OPIN BIOL TH, V7, P1207, DOI 10.1517/14712598.7.8.1207
   Thornton AM, 2004, EUR J IMMUNOL, V34, P366, DOI 10.1002/eji.200324455
   Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101
   Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437
   Wright GP, 2009, P NATL ACAD SCI USA, V106, P19078, DOI 10.1073/pnas.0907396106
   Yan ZH, 2009, NAT CHEM BIOL, V5, P721, DOI 10.1038/nchembio.212
   Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774
NR 57
TC 69
Z9 69
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 22
PY 2010
VL 5
IS 7
AR e11726
DI 10.1371/journal.pone.0011726
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 630AN
UT WOS:000280243300026
PM 20668510
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Janson, PCJ
   Winerdal, ME
   Marits, P
   Thorn, M
   Ohlsson, R
   Winqvist, O
AF Janson, Peter C. J.
   Winerdal, Malin E.
   Marits, Per
   Thorn, Magnus
   Ohlsson, Rolf
   Winqvist, Ola
TI FOXP3 Promoter Demethylation Reveals the Committed Treg Population in
   Humans
SO PLOS ONE
LA English
DT Article
AB Background: Naturally occurring thymus derived regulatory T cells (Tregs) are central in the maintenance of self-tolerance. The transcription factor FOXP3 is crucial for the suppressive activity of Tregs and is considered the most specific marker for this population. However, human non regulatory T cells upregulate FOXP3 transiently upon activation which calls for other means to identify the Treg population. Since epigenetic mechanisms are involved in the establishment of stable gene expression patterns during cell differentiation, we hypothesized that the methylation profile of the FOXP3 promoter would allow the distinction of truly committed Tregs.
   Methodology/Principal Findings: Human CD4(+) CD25(hi) Tregs displayed a demethylated FOXP3 promoter (1.4%+/-0.95% SEM methylated) in contrast to CD4(+) CD25(lo) T cells which were partially methylated (27.9%+/-7.1%). Furthermore, stimulated CD4(+)CD25(lo) T cells transiently expressed FOXP3 but remained partially methylated, suggesting promoter methylation as a mechanism for regulation of stable FOXP3 expression and Treg commitment. In addition, transient FOXP3 expressing cells exhibited suppressive abilities that correlate to the methylation status of the FOXP3 promoter. As an alternative to bisulphite sequencing, we present a restriction enzyme based screening method for the identification of committed Tregs and apply this method to evaluate the effect of various culturing conditions. We show that a partial demethylation occurs in long-term cultures after activation, whereas the addition of TGF-beta and/or IL-10 does not induce any additional change in methylation level.
   Conclusions/Significance: The unique FOXP3 promoter methylation profile in Tregs suggests that a demethylated pattern is a prerequisite for stable FOXP3 expression and suppressive phenotype. Presently, FOXP3 is used to identify Tregs in several human diseases and there are future implications for adoptive Treg transfer in immunotherapy. In these settings there is a need to distinguish true Tregs from transiently FOXP3(+) activated T cells. The screening method we present allows this distinction and enables the identification of cells suitable for in vitro expansions and clinical use.
C1 [Janson, Peter C. J.; Winerdal, Malin E.; Marits, Per; Winqvist, Ola] Karolinska Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden.
   [Thorn, Magnus] South Stockholm Gen Hosp, Dept Surg, Stockholm, Sweden.
   [Ohlsson, Rolf] Uppsala Univ, Evol Biol Ctr, Dept Dev & Genet, Uppsala, Sweden.
RP Janson, PCJ (reprint author), Karolinska Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden.
EM ola.winqvist@karolinska.se
FU Swedish cancer society; Cancer and Allergy society; Hedlunds foundation;
   Lundberg foundation; Gustav V. foundation; Selander foundation;
   Soderbergs foundation
FX This work was supported by the Swedish cancer society, the Cancer and
   Allergy society, the Hedlunds foundation, the Lundberg foundation,
   Gustav V. foundation, the Selander foundation and the Soderbergs
   foundation.
CR Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685
   Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Bas A, 2004, SCAND J IMMUNOL, V59, P566, DOI 10.1111/j.0300-9475.2004.01440.x
   Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774
   Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1039/ni887
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Clark LB, 1999, J IMMUNOL, V162, P2546
   Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x
   Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   GODFREY VL, 1991, AM J PATHOL, V138, P1379
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   Kim JM, 2006, IMMUNOL REV, V212, P86, DOI 10.1111/j.0105-2896.2006.00426.x
   Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265
   Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158
   Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007
   Mantel PY, 2006, J IMMUNOL, V176, P3593, DOI 10.4049/jimmunol.176.6.3593
   Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016
   Park HB, 2004, INT IMMUNOL, V16, P1203, DOI 10.1093/intimm/dxh123
   Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085
   Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q
   Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287
   TRAN DQ, 2007, BLOOD
   Walker MR, 2005, P NATL ACAD SCI USA, V102, P4103, DOI 10.1073/pnas.0407691102
   Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Wilson CB, 2005, SEMIN IMMUNOL, V17, P105, DOI 10.1016/j.smim.2005.01.005
   Wu B, 2007, J IMMUNOL, V178, P3688, DOI 10.4049/jimmunol.178.6.3688
   Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165
   Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747
NR 42
TC 151
Z9 163
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2008
VL 3
IS 2
AR e1612
DI 10.1371/journal.pone.0001612
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 367XR
UT WOS:000260586400005
PM 18286169
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

EF